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Abstract: Proteins are a large group of biomolecules that are capable of a broad range of 
biochemical functions. Utilizing the biochemical capabilities of proteins is of significant 
interest toward improving human health. For proteins to be useful, they must be 
appropriately delivered to perform the task for which they are needed. This work 
investigates how the cationic copolymer, poly-l-lysine-grafted-polyethylene glycol (PLL-
g-PEG), may be used to modify proteins in order to improve aspects of their delivery. 
PLL-g-PEG was found to associate with a model protein, BSA, to form nanoparticle 
complexes through electrostatic interaction between the protein and copolymer. 
Molecular characteristics of the copolymer, such as PLL molecular weight and PEG 
grafting were found to impact both the ability of the copolymer to associate with the 
protein and also the stability of the resulting complexes. The nanoparticle complexes 
were functionalized with cell-penetrating peptides (CPPs) to impart the ability to enter 
into a broad range of cell types. The impact CPP functionalized nanoparticle complexes 
had on albumin in the physiological environment was investigated. CPPs were found to 
induce conformational changes in albumin, with the extent of albumin denaturation 
correlating with CPP charge and arginine content. The denaturation of albumin played a 
role in uptake of the nanoparticle complexes by macrophages. Cell specific delivery of 
PLL-g-PEG nanoparticle complexes was demonstrated by functionalizing PLL-g-PEG 
with an anti-PSMA monoclonal antibody. The anti-PSMA-PLL-g-PEG nanoparticle 
complexes were able to deliver a cytotoxic protein, glucose oxidase, to prostate specific 
membrane antigen (PSMA)-expressing LNCaP cells, while inducing negligible 
cytotoxicity in PC-3 cells, which lack PSMA. Together, these studies demonstrate the 
wide utility of PLL-g-PEG to provide a base for altering the characteristics of proteins 
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1.1 Proteins as Therapeutics and Challenges to Delivery 
Proteins are relatively large biomolecules that, due to their vast variety of 
potential structures, carry out a wide number of biochemical tasks that are needed for the 
normal function of cells, tissues, and organs within an organism. When a protein is not 
present in quantities needed or is not sufficiently active, cells are unable to function 
normally, resulting in poor health and disease. Many health conditions are a result of a 
loss of appropriate protein function. For this reason, the ability to replace proteins that 
have lost function or to utilize proteins that can be used to accomplish biochemical tasks 
is of significant interest to improve human well-being. 
 Although some proteins, such as insulin, albumin, and antibodies, have already 
been successfully applied toward the improvement of human health, other proteins still 
face challenges to their use [1]. There may be several reasons that a protein is not able to 
be utilized therapeutically, but two common reason are poor delivery to specific sites 
within the body and rapid removal from circulation due to immunogenicity [1, 2]. A 
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protein may also not be adequately delivered if it needs to be delivered into the cell interior, 
as the cell membrane is effective at prohibiting large hydrophilic biomolecules like proteins 
from crossing into the cell interior [1, 3]. The development of novel approaches to either 
modify proteins or to encapsulate them into drug delivery vehicles has, therefore, become of 
substantial interest to attempt to overcome challenges to poor protein delivery.  
1.2 Cationic Copolymers and Nanoparticles for Protein and Drug Delivery 
Nanomaterials have become a popular approach to deliver therapeutics, ranging from 
small molecule anti-cancer drugs to macromolecules such as peptides, proteins, and nucleic 
acids [4, 5]. Nanomaterials can include a wide variety of structures, including nanoparticles 
(NPs), nanorods, nanosheets, and nanotubes, but NPs are one of the most common 
nanomaterials for drug delivery. The advantage of NP-based systems is that, through the 
manipulation of the material used to construct the NP, the delivery and release of therapeutic 
cargos can potentially be better controlled than that of the non-encapsulated molecules [6]. 
Additionally, the nano-scale is conducive for the passage and interaction of therapeutics with 
both the extracellular environment as well as components of the cell interior [6, 7]. NPs can 
be tailored with functionalities to protect their cargos during extracellular transport, as well 
as with mechanisms to allow for cell binding and internalization during delivery [8-10]. 
Despite all of these advantages, there remains significant room for improvement in 
production and efficiency of many NP-based drug delivery systems [11].  
One of the most important aspects of NP delivery systems is the material used to 
synthesize the NP. Although several biomaterials have been developed that have 
characteristics conducive to drug delivery, our group has particular interest in the cationic 
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grafted copolymer, poly-l-lysine-grafted-polyethylene glycol (PLL-g-PEG, Figure 1.1). One 
part of the PLL-g-PEG copolymer, polyethylene glycol (PEG), is a hydrophilic polymer that 
has been widely used to reduce clearance and improve the biocompatibility of biomaterials, 
NPs, and pharmaceutics [12]. PEG coating or PEGylation prevents liver and kidney 
clearance of molecules, and is already being used commercially to improve the circulation 
characteristics of several proteins such as asparaginase (Oncaspar®) and interferon 
(Pegasys®) [13-15]. 
  
Figure 1.1. Chemical Structure of PLL-grafted-PEG. 
One of the reasons PEG is able to impart these beneficial properties is through the 
reduction of serum protein adsorption onto NP surfaces. PEG has been used to prevent 
protein adsorption onto NPs and to reduce NP uptake by cells to about 10% of comparable 
bare NPs [16]. Others have established that PEG molecular properties, such as molecular 
weight and extent of copolymer grafting, also impact serum protein adsorption onto NPs. 
Rausch et al. found that 10-20% PEGylation of PLL was sufficient to prevent large 
aggregates from forming between the polymer and other serum proteins [17]. Additionally, 
Gref et al. found  5kDa PEG best prevented plasma proteins from being adsorbed on the 
surface of polylactic acid (PLA) NPs [18]. The work of these studies provided guidelines 
toward the grafting of PEG onto PLL as part of the synthesis of PLL-g-PEG NPs, which will 




The ϵ- amino groups of PLL-g-PEG are cationic at physiological conditions (pI 9.5), 
allowing the polymer to electrostatically self-assemble with negatively charged molecules to 
form into a type of NP, often called a polyion complex [19-23]. Synthetic gene delivery 
applications have utilized PLL and other cationic polymers to self- assemble with nucleic 
acids and utilize specialized functionalities to enhance their delivery efficiency [24-26]. In 
addition to nucleic acids, charged polymers and copolymers have also been used to deliver 
proteins, such as lysozyme, IgG, butyrylcholinesterase (BChE), superoxide dismutase 
(SOD1), and catalase [27-32]. These studies suggested the significant potential of PLL-g-
PEG copolymers to self-assemble with a wide variety of proteins to form NP complexes and 
alter the delivery of proteins. However, the characteristics of cationic copolymers, such as 
PLL-g-PEG, best suited for protein delivery have not been well described. This prompted us 
to investigate what copolymer structural characteristics significantly impact protein 
association with the PLL-g-PEG during NP synthesis and what characteristics this imparts on 
the resulting NP complexes. 
1.3 Identifying PLL-g-PEG Characteristics Beneficial to Protein Delivery 
The first section describing experimental work, Chapter 3, focused on identifying 
PLL-g-PEG cationic copolymer characteristics that are likely to be favorable for the delivery 
of proteins [9]. A library of PLL-g-PEG copolymers with varying structural characteristics, 
such as PLL molecular weight and PEG grafting ratio, were synthesized to better understand 
what aspects of cationic copolymers significantly impact protein delivery. In this section of 
the work, Chapter 3 (Figure 1.2.), our group encapsulated a model protein, bovine serum 
albumin (BSA), to better understand how properties of the copolymer materials impact 
delivery characteristics of the encapsulated protein. A broad range of PLL molecular weights 
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were grafted with 2 and 5 kDa PEG at different ratios to both encapsulate the protein into 
nanoscale complexes and to also enable the future planned multi-functionalization of the NP 
complexes with targeting and cell internalization ligands. Ligand functionalization and cell 
delivery will be discussed further in later sections of the Introduction and in subsequent 
chapters. BSA was used as a model protein for these studies, due to its availability and high 
degree of similarity in isoelectric point and molecular weight to recombinant BChE (BSA: 
pI; 4.7, MW; 66.5 kDA; BChE: pI; 5.0, MWmonomer; 85 kDa), a protein of much more 
significant interest in improving its delivery [30, 33-35]. Our group found that minor 
alterations in PLL-g-PEG material properties, such as polymer molecular weight, could 
impart unique characteristics to the PLL-g-PEG/BSA NP complex, such as variation in 
protein-copolymer association and resistance to NP complex instability.  Additionally, while 
BSA could not be released from the NP complex, the protein retained activity toward a small 
molecule substrate. 
 
Figure 1.2. Chapter 3: Effect of cationic grafted copolymer structure on the encapsulation of bovine 
serum albumin. 
Forming NP complexes with BSA and cationic copolymers aimed to serve as a guide 
for forming similar complexes with BChE. BChE is an enzyme of great interest in defense 
and anti-terrorism applications, due to its ability to bind and scavenge organophosphate type 
toxicants that compose several types of chemical weapons [33]. Recombinant BChE has the 
potential to be economically produced compared to native forms of the enzyme, but is 
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cleared from blood circulation too quickly to provide protection against organophosphate 
poisoning for prolonged periods of time [33]. We were part of a collaborative team that 
found BChE formed NP complexes with PLL-g-PEG, which also retained significant enzyme 
activity, organophosphate binding, and resistance to proteolysis [36, 37]. With the ability to 
form PLL-g-PEG/BChE NP complexes encapsulating functional enzyme, our groups 
proceeded to functionalize BSA and BChE NP complexes with CPPs and targeting ligands to 
attempt to impart the ability bind and enter red blood cells. 
1.4 Ligand Functionalization and Cell Penetrating Peptides 
One approach that has been shown to improve cellular binding of polyion NPs is the 
use of targeting ligands to bind to cell-specific molecular features on the cell surface [38]. 
Our group took a similar approach to functionalize our NPs, using two ligands to aid NP 
binding and internalization. The first ligand was a 2 kDa, peptide called ERY1, which was 
developed by Kontos et al. [39]. ERY1 binds to Glycophorin A, an abundant protein on red 
blood cells (RBCs) [39]. Using RBCs or RBC-like materials as carriers can potentially 
improve the circulation characteristics of  proteins or NPs, which naturally circulate for long 
periods of time [40]. ERY1 has been used to transport proteins and nanoparticles to RBCs, 
while having minimal impact on RBC function [41, 42]. Our group developed NPs that have 
been functionalized with ERY1 that were able to bind to RBCs in vitro and in a model 
system of simulating RBCs under flowing conditions [43, 44]. The second ligand that was 
used to functionalize NP complexes is another 2 kDa peptide called low molecular weight 
protamine (LMWP). LMWP is a highly cationic cell-penetrating peptide (CPP) that was 
developed by Park et al. for transporting siRNA and protein cargos into several cell types, 
including RBCs [45-48]. CPPs, as their name suggests, are peptides with the ability to 
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traverse the cell membrane. Our group aimed to similarly use the LMWP CPP to deliver NPs 
into RBCs. Due to our group’s interest in utilizing CPPs and the wide applicability of these 
peptides to deliver therapeutic cargos, we briefly reviewed CPPs from their discovery to their 
recent applications, which is found in Chapter 2 of this work [49]. Although CPPs are not the 
primary focus of this work, our group’s efforts to apply them toward improving the NPs our 
group produced made a review on the subject beneficial. While reviewing CPPs, it was found 
that most work investigating CPPs focused on their transport through cells or their 
application, but the interactions of CPP-functionalized NPs with proteins in the biological 
environment in their route to delivery have received considerably less attention. As little 
exploration on the interactions that serum proteins with CPP-functionalized NPs had been 
done, another portion of this work aimed to combine aspects of what is known about the 
protein corona of NPs in order to learn more about utilizing CPPs for NP delivery. 
1.5 Nanoparticles and the Protein Corona 
Recently, Cedervall et al. discovered that NPs placed in a biological medium become 
surrounded by a halo of proteins, also known as a “protein corona” [50, 51]. The protein 
corona is akin to the Vroman effect, in which surfaces that come into contact with plasma 
become coated with proteins [52, 53]. This protein corona is highly important as the corona 
confers a new biological identity to NPs, altering how NPs interact with cells and other 
components of the biological environment [54-56]. For example, NP clearance by 
macrophages and half-life in circulation have been correlated to individual corona proteins of 
polystyrene NPs [57]. Tenzer et al. also found that factors, such as thrombocyte activation, 
hemolysis, and endothelial cell death can all be induced by protein corona formation on 
polystyrene and silica NPs [58]. These studies, along with several others, demonstrate that 
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the protein corona confers a new biological surface to NPs that may significantly impact how 
the NPs interact with cells [59-61]. Therefore, in order to design novel biomaterials and 
nanodevices intended for therapeutic delivery, characterizing the protein corona is an 
important factor for using materials that will ultimately perform best in vivo [58, 62].  
1.6 Proteins of the Nanoparticle Protein Corona 
Characterizing what types of individual and groups of proteins bind to NPs is one key 
part to understanding the corona composition and predict biological outcomes from protein 
binding. There are over 3,700 proteins in the plasma, each of which could compose part of a 
NP protein corona [63]. Some of the most common proteins observed on almost all studied 
NPs are also some of the most abundant proteins in plasma, such as albumin, IgG, and 
fibrinogen [64]. These and other groups of proteins that bind and coat the NP can each 
influence how NPs interact with cells [53]. For example, NPs that primarily bind groups of 
proteins called dysopsonins, proteins inhibitory to cellular uptake, could often be expected to 
aid the NPs persistence in circulation [64]. Some commonly observed typical dysopsonins 
found to bind to NPs include albumin and apolipoproteins [64]. Others have observed 
opsonins, such as complement proteins C3, C4, C5, and IgG, in the NP protein corona, which 
increases cellular uptake [65, 66]. Due to the large number of effects that different proteins 
may have on NP delivery, characterizing which proteins bind to different types of NPs is an 
important part to more accurately predicting how successful NPs will be at delivery.  
1.7 Nanoparticle Binding and Uptake with the Protein Corona 
  The protein corona has been found to be critically important in NP-cellular 
interactions, such as cell binding and uptake. For example, it has been found that the protein 
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corona adversely affects NPs that have been functionalized with targeting ligands, reducing 
the ability of ligands to target NPs to specific cell types  [67, 68]. The protein corona also 
affects the cellular uptake of NPs. Caracciolo et al. found that adsorption of the protein 
corona around DC-DOPE-cholesterol liposomes, encapsulating DNA, strongly influenced the 
liposome cellular uptake mechanism, altering uptake from clatherin- to caveolae-mediated 
endocytosis, thereby improving transfection efficiency in the presence of serum [69]. 
Additionally, Ritz et al. formed protein coronas with individual proteins found as part of the 
protein corona of NPs and discovered that ApoA4 and ApoC3 proteins decreased cellular 
uptake, while ApoH increased cellular uptake [70]. These studies indicate that individual 
proteins within the protein corona, in addition to NP surface properties, can potentially play 
an important role in the cellular uptake of NPs.  
The protein corona significantly impacts macrophage binding and uptake of NPs. 
Macrophages, particularly in the liver and spleen, are often responsible for most of the 
removal of nanomaterials administered in vivo [71]. The enrichment of certain proteins on 
the NP surface have been found to be closely tied with either preventing or promoting 
macrophage NP uptake [72]. For example, the association of the protein clusterin with PEG 
was found to be correlated with significantly reduced macrophage uptake [73]. Conversely, 
NP surface properties, such as hydrophobicity, have been found to promote corona formation 
which favor greater macrophage uptake [72].  In each of these cases, the type of NP surface 





1.8 Protein Structure Within the Nanoparticle Protein Corona 
Individual proteins within the NP protein corona may also act to favor or inhibit NP 
uptake, depending on the structural state of the protein [74]. Albumin, one of the most 
abundant proteins in blood, was found by multiple groups to undergo denaturation that lead 
to NP uptake by macrophages and other cell types [57, 60]. These structural changes were 
observed to be induced by cationic NPs, however, other types of NPs have also been 
observed to cause protein denaturation [60, 74].  
Although the protein corona has been characterized for several NP systems, including 
gold, silica, polystyrene, and liposomes, the corona for most NPs, particularly those of 
polymeric gene and protein vectors such as PLL-g-PEG or those that have been 
functionalized with ligands, have not been extensively studied [54, 62, 75, 76]. Because of 
our group’s interest in delivering CPP functionalized PLL-g-PEG NP to RBCs in vivo, 
another major aim of this work was to determine how albumin binding to CPP-functionalized 
NP complexes impacted albumin structure and if this structural change could lead to uptake 
of the complexes by macrophage cells, which is described in Chapter 4 (Figure 1.3).  
 




Because most CPPs are highly charged, CPP functionalized PLL-g-PEG complexes 
were also expected to cause similar denaturation of albumin as that observed in the studies 
described earlier [57, 60]. Determining what CPP characteristics induce lower extents of 
albumin denaturation and therefore potentially less macrophage uptake could potentially 
serve to guide in the design of CPP-functionalized NP protein delivery systems. 
1.9 Targeted Nanoparticle Delivery 
CPPs are effective at delivering cargos into a wide variety of cells. However, this 
property also results in poor cell specificity. Because PLL-g-PEG NP binding to targeted cell 
types was also an important component to our group’s efforts to deliver proteins, a ligand 
with greater cell specificity was needed to be able to better control the delivery of PLL-g-
PEG NP complexes. Chapter 5 (Figure 1.4) describes another part of our group’s efforts to 
demonstrate that delivery of PLL-g-PEG NP complexes can be preferentially delivered to 
specific cells. While much of our work has focused on attempting to improve the binding and 
internalization of PLL-g-PEG NP complexes to red blood cells, we also aimed to explore 
other applications for which these NP complexes could be used. In this section, targeted 
delivery of a cytotoxic protein, glucose oxidase (GOX), was delivered to cancer cells 
expressing prostate membrane specific antigen (PSMA). GOX catalyzes the oxidation of 
glucose into gluconic acid and hydrogen peroxide [77]. Hydrogen peroxide is cytotoxic due 
to the oxidative damage it causes to lipids, proteins, and nucleic acids within cells [78]. GOX 
has long been of interest as an anti-cancer agent, but localized delivery of the protein to 
tumors is necessary for the enzyme to be cytotoxic to tumors and not the host [79-81]. By 
delivering a cytotoxic protein intracellularly to PSMA-expressing cells, we demonstrate that 
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PLL-g-PEG NPs, encapsulating GOX and other proteins, can be selectively delivered to cells 
of interest. 
 
Figure 1.4. Chapter 5: Intracellular delivery of glucose oxidase for enhanced cytotoxicity to PSMA-
expressing prostate cancer cells. 
1.10 Summary 
The overall aim of this work was to use the cationic polymers and other biomaterials 
to give proteins new properties that improve their delivery. We focused primarily on cationic 
copolymers of PLL-g-PEG, which we show are able to effectively associate with proteins 
and self-assemble into NP complexes. Chapter 3 of this work focuses on how structural 
characteristics of the copolymer impact both association of a model protein, BSA, into NPs 
and how this impacts several aspects of protein delivery. Upon demonstrating that proteins 
could be formed into NP complexes, our group proceeded to functionalize the NP complexes 
with CPPs to enable them to be more efficiently delivered intracellularly. Chapter 2 of this 
work reviews the origins and current applications of CPPs. Chapter 4 of this work 
investigates the role of serum albumin in the protein corona on the uptake of CPP 
functionalized NPs by macrophage cells. As one of the primary drawbacks of utilizing CPPs 
for the delivery of therapeutic cargos is poor cell specificity, Chapter 5 of this work focuses 
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on antibody functionalization of the NP complexes to demonstrate that specificity for 
particular cells can be imparted on these complexes. This work consisted of delivering the 
cytotoxic protein, GOX, as part of the PLL-g-PEG NP complex to PSMA-expressing prostate 
cancer cells. Collectively, these studies demonstrate that PLL-g-PEG NP complexes can be 
tuned to interact with the biological environment in many different ways and also show 











Cells are adept at preventing small molecules, proteins, genetic material, and larger 
protein complexes from entering in a nonspecific manner.  The exterior of the cell is 
composed of a fluid phospholipid bilayer that is coated with proteoglycans.  The lipid 
bilayer that makes up the cell membrane has a polar surface with a nonpolar interior.  
Together, the contrasting nature of the membrane lipid bilayer prevents most molecules 
from passively diffusing directly through the cell membrane.  Instead, cells use a 
combination of ion channels and carrier proteins to transport important molecules such as 
ions, sugars, and amino acids across the lipid bilayer.  Cells also may use endocytosis or 
exocytosis to transport material in bulk across the membrane. 
While precise control of transport across the cell membrane is generally 
advantageous for the cell, many potential therapeutic drug targets are located within the 
interior of the cell and require entry of pharmaceutical molecules in order to be
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effectively treated.  This has long been a challenge in the field of gene therapy [82], 
where a therapeutic gene must not only be transported across the cell membrane, but 
must also be transported to the nucleus of the cell where it can be transcribed and 
translated into a therapeutic protein.  Similarly, siRNA must also be transported across 
the cell membrane to the cell cytosol where it can act on the mRNA of the gene being 
silenced.  Likewise, there are a growing number of intracellular targets for cancer therapy.  
In some cases, cancer treatment may benefit from the intracellular delivery of a particular 
protein, such as a cytotoxic protein or a tumor suppressor protein that is not natively 
expressed in an active state [83-86].  Cancer therapy may also benefit from delivery of 
peptides that act as inhibitors.  Examples include peptides that act by preventing STAT3 
from binding to DNA in tumor cells [87], peptides that inhibit angiogenesis by hindering 
β protein kinase C [88, 89], and peptides that induce apoptosis by disrupting the 
membrane of mitochondria [90, 91].  
Large macromolecular drugs, such as genetic material or proteins, are often 
designed to be transported into target cells through either non-specific or receptor-
mediated endocytosis.  In contrast, many small molecule therapeutics are believed to 
undergo transport through some combination of passive diffusion and carrier-mediated 
transport.  There is currently a very spirited debate on where this balance falls [92, 93].  
Dobson and Kell have argued previously that carrier-mediate transport is the predominant 
mechanism for drug entry [94], while Sugano et al. made a case for a combination of both 
passive diffusion and carrier-mediate transport [95]. 
Regardless of how much each mechanism plays in the transport of the drug, cell 
entry remains a focus for those working in drug design and discovery.  An exciting and 
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relatively new approach to transporting pharmaceutical agents into cells is making use of 
cell-penetrating peptides (CPPs) (recent reviews include: [96-99]).  CPPs are relatively 
short peptides, typically less than 30 amino acids, that have been shown to be relatively 
nontoxic and capable of traversing the cell membrane.  They are typically classified as 
either polycationic, amphipathic, or hydrophobic.  Most importantly, they have been used 
to facilitate the transport of many different therapeutic agents into cells, including 
plasmid DNA, siRNA, therapeutic proteins, viruses, imaging agents, and other various 
nanoparticles. 
2.2 Discovery of Cell-Penetrating Peptides 
Some of the first studies that led directly to the discovery of CPPs were published in 
1988.  Up until that time, transport of proteins and peptides through the cell membrane 
was generally regarded as difficult given their large molecular weight and hydrophilicity 
[100].   Frankel and Pabo, however, discovered that purified trans-activator protein 
(TAT), from human immunodeficiency virus type 1 (HIV-1), was readily taken up from 
cell culture medium by HL3T1 cells [101].  They also showed that uptake of TAT was 
enhanced when chloroquine was added to the medium, suggesting that uptake was likely 
occurring through endocytosis.  At the same time, Green and Loewenstein independently 
demonstrated that only a portion of the 86 amino acid TAT protein was necessary for 
both cellular uptake and enzymatic activity [102].  By investigating various N-terminal 
and C-terminal deletion mutants, Green and Loewenstein showed that TAT (37 – 57) 
entered cells and retained ~ 40 % of the activity of the full-length TAT protein.   
Nearly 10 years after the initial discovery of the TAT peptide, even smaller TAT 
peptides were shown to translocate through the cell membrane.  In one study, Vivès et al. 
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found that TAT (48 – 60) was able to enter cells and that cellular uptake of the peptide 
was not inhibited at 4 ºC [103], implying an alternative to the endocytic mechanism 
suggested earlier by the findings of Frankel and Pabo.  Further, Vivès et al. were able to 
rule out potocytosis and caveolae-mediated endocytosis by using respective pathway 
inhibitors.  At the same time, Vivès et al. published a second paper in which they showed 
that the C-terminal end of the TAT peptide could be further truncated to TAT (48 – 57) 
without significant loss of translocation ability [104].  Park et al. followed up this study 
showing that the peptide could be truncated even more to TAT (49 – 57) [105]. 
Around the same time as the discovery of TAT, the Prochiantz group identified a 60 
amino acid region of the Drosophila antennapedia homeobox protein (pAntp) that was 
capable of penetrating differentiated neurons [106].  Joliot et al. were investigating the 
effects of injecting the DNA-binding peptide on nerve cell differentiation when they 
discovered that the peptide was able to penetrate differentiated nerve cells (i.e., without 
injection) and accumulate in the nucleus.  While the entry mechanism was unclear, they 
were able to rule out internalization due to cell damage by comparing the uptake of the 
pAntp peptide with proteolytic fragments of fluorescent ovalbumin. 
Prochiantz’s group followed this initial report with a study investigating the uptake 
mechanism and also the minimal sequence required for cell entry [107].  Earlier studies 
had shown that the third α-helix of the pAntp peptide, which consists of three α-helices 
with a β-turn between the second and third helix, may be especially important in cell 
entry; there is a high degree of phylogenetic kinship in the third α-helix and studies 
showed that internalization of the peptide was especially sensitive to mutations in this 
region [108].  Derossi et al. went on to show that truncation of the third α-helix by 
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deletion of the C-terminal glutamate produced a 16 amino acid peptide capable of 
translocating through cell membranes [107].  Further, they were able to show that entry 
of the peptide was not limited to neuronal cells nor was it dependent on binding a specific 
transporter.  Once again, the mode of cell entry was not clear, but this time Prochiantz’s 
group demonstrated that internalization was energy-independent, occurring at 4 °C and 
avoiding the endolysosomal uptake pathway. 
Hundreds of additional CPPs have been discovered in the two decades that have 
passed since the discovery of TAT and the pAntp peptide.  Table 2.1 provides a short list 
of some of these peptides, their source, peptide sequence, and examples of the cargo they 
have been used to transport.  CPPs are typically classified by either their physical-
chemical properties or by their origin.  The peptides listing in Table 2.1 have been 
grouped based on their physical-chemical properties: cationic, amphipathic, or 
hydrophobic.   
Table 2.1. Examples of some common cell-penetrating peptides and their applications. 
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Similar to TAT and the pAntp peptide, many of the CPPs were derived from natural 
proteins or peptides, including viral proteins, heparin-binding proteins, DNA/RNA-
binding proteins, homeoproteins, signal peptides, and antimicrobial peptides.  The VP22 
peptide, for example, was derived from a herpes virus structural protein [127].  The 
origin of DPV3 was a heparin binding protein [123].  TAT, which comes from the HIV-1 
virus, was derived from the RNA-binding, trans-activator protein.  The origin of the 
pAntp peptide was a homeoprotein, which is a class of DNA-binding proteins.  K-FGF 
was derived from the signal peptide in Kaposi’s sarcoma fibroblast growth factor [133], 
and while none are included in Table 2.1, there are many known CPPs that were derived 
from antimicrobial peptides such as Bac7, buforin 2, tachyplesin and melittin [143-146]. 
Some CPPs are derived from a combination of natural proteins or peptides and are 
referred to as chimeric.  Transportan and Pep1 are two peptides listed in Table 1 that are 
chimeric.  Transportan was produced by combining the neuropeptide galanin and the 
wasp venom peptide mastoparan [124].  A common approach with chimeric CPPs has 
been to combine signal peptides with NLS peptides.  Pep1 is a result of this approach, 
where a tryptophan-rich hydrophobic domain that associates with cell membranes has 
been fused to a SV40 NLS peptide [130]. MPG is another chimeric peptide produced 
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using this approach.  MPG combines the SV40 NLS peptide with a signal peptide taken 
from HIV glycoprotein 41 [147]. 
Synthetic peptides are the final classification group based on the origin of the CPP.  
Model amphipathic peptide (MAP) and polyarginine are both listed in Table 2.1 and were 
two of the first synthetic peptides developed.  These early synthetic peptides were 
designed to mimic CPPs based on natural proteins.  For example, polyarginine was 
investigated for its cell-penetrating ability because of its similarity to TAT, which also 
has a large number of arginine residues [118, 120].  MAP was meant to be a model 
peptide that had amphipathic alpha helical secondary structure, which could be used to 
study if unique structural features were necessary for membrane passage, as was thought 
to be the case with the pAntp peptide [148].  Since the discovery of these two synthetic 
peptides, and many more like them, molecular cloning techniques and screening tools 
such as phage display have enabled high-throughput screening of large peptide libraries.  
These libraries have yielded additional synthetic CPPs that, unlike polyarginine and MAP, 
tend to be more hydrophobic and lack amphipathic structure [149].  
Lastly, there has been recent interest in developing non-peptide mimics of CPPs.  
These mimics of CPPs are typically built upon polymer backbones.  By modifying the 
polymer side chains an array of polymers have been synthesized that show robust 
transduction of cells.  While these non-peptide mimics of CPPs are not the focus of this 
paper, the interested reader is referred to a recent review on the subject [150].  
2.3 Mechanism of Cellular Entry   
From the beginning there has been considerable interest in exactly how CPPs enter 
cells.  The mechanisms are still not entirely understood, but what we are beginning to 
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recognize is that the mechanisms by which CPPs enter cells seems dependent on not only 
the type of CPP but also its concentration [151], the cargo that it transports, and the cell 
line on which it is being tested.   Arriving at this understanding has not been easy, as 
early studies provided contradictory findings.  As described above, Frankel and Pabo 
(1988) found that chloroquine enhanced the uptake of Tat peptide, implying that an 
endocytic mechanism was likely [109].   Vives, Brodin, and Lebleu (1997), however, 
showed that the uptake of TAT occurred at 4 °C, which implied that endocytosis was 
unlikely [103].  In addition, the Prochiantz group showed that pAntp was also able to 
enter cells at 4°C , thereby lending further evidence to an energy-independent, non-
endosomal uptake mechanism for CPPs [107].  The concern with these studies, and many 
other early studies, was that they predominantly relied on fluorescence microscopy of 
fixed cells or flow cytometry to measure uptake of CPPs.  In 2002, it was shown that 
fixation of cells could lead to artifactual redistribution of peptides that had otherwise 
simply been bound to the cell membrane [152, 153].  Both of these studies also showed 
that despite extensive washing, cationic CPPs remained bound to the cell membrane, 
which could erroneously lead one to conclude from flow cytometry that the CPPs had 
been internalized.  Taking into account the issues with flow cytometry and cell fixation, 
Richard et al. (2003) were able to show that the uptake of the TAT peptide is indeed 
inhibited at 4 °C.  Endosomal distribution and the kinetics of uptake also helped confirm 
that TAT, under the conditions described in the study, was internalized in an endocytic 
manner.         
Figure 2.1 summarizes the different routes by which a CPP might enter a cell.  
While direct translocation across the cell membrane occurs in some cases, it is generally 
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accepted that most CPPs and CPP-cargo complexes enter cells through endocytosis, 
including macropinocytosis, clathrin-mediated endocytosis, and caveolae/lipid raft-
mediated endocytosis.  Some CPPs have been shown to use more than one of these 
internalization routes and to sometimes use different routes simultaneously.  
Investigations into the TAT peptide, for example, have shown that TAT is internalized 
through macropinocytosis [154], clathrin-mediated endocytosis [155], and caveolae-
mediated endocytosis [156]. 
 
Figure 2.1. Proposed mechanisms for cellular entry of cell-penetrating peptides. 
 
In spite of some of the early errors assessing cellular entry, CPPs have been shown 
to directly penetrate the cell membrane in a non-endocytic manner, especially at high 
concentrations of the peptide [157, 158].  Many different models have been proposed to 
explain this observation, a few of which include inverted micelles, transient toroidal 
pores, and adaptive translocation.  
Derossi et al. were the first to suggest CPPs may be entering through an inverted 
micelle [159].  They hypothesized that the pAntp was entering cells through either an 
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inverted micelle or through fluid phase pinocytosis.  The authors went on to provide 
ample justification for the inverted micelle model, including an explanation that 
substitution of the CPP tryptophan residues, which are known to induce formation of 
inverted micelles, abolished cell penetration. 
 The formation of transient toroidal pores, similar to the carpet model [160], has 
also been suggested as a possible mechanism for direct translocation.  Molecular 
dynamics simulations of the TAT peptide interacting with a lipid bilayer showed that at 
high concentrations of the TAT peptide transient pores could form in the membrane [161].  
The model showed that attraction of the TAT peptide with the phospholipid head groups 
on both the outer and inner lipid leaflets leads to a thinning of the lipid bilayer and 
ultimately penetration of the membrane.  The lack of observable membrane leakage has 
led many to discount this mechanism. The transient nature of the pores, however, 
combined with the cellular membrane repair response may explain why no membrane 
leakage or cell damage is observed [162].  
Another proposed mechanism for direct translocation of the cell membrane by 
cationic CPPs is adaptive translocation.  The idea that a hydrophilic, charged peptide 
could directly migrate through the hydrophobic lipid bilayer initially seems improbable.  
Rothbard et al., however, proposed a mechanism by which they suggested cationic 
peptides form transient ion pair complexes with negatively charged membrane 
components; the reduced, yet still positive charge associated with the ion pair complex 
allows the peptide to adaptively diffuse through the cell membrane, where the driving 
force for diffusion is the membrane potential [163].  Rothbard et al. supported their 
proposed model by explaining that reduced membrane potential resulted in reduced 
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cellular uptake of the peptide without any noticeable effect on endocytosis.  Further, they 
showed that increased membrane potential resulted in increased cellular uptake of CPPs. 
In addition to the models described here, there may be a newly discovered model 
that is not entirely understood.  A recent study by Hirose et al. found that arginine-rich 
CPPs conjugated to hydrophobic small molecules directly translocated the cell membrane 
at sites where the peptides formed unique “particle-like” structures composed of multiple 
vesicles on the plasma membrane [164].  Penetration into the cell occurred through both 
direct translocation and endocytosis.  Further, direct translocation was found to be 
dependent on the presence of the hydrophobic fluorescent dye Alexa488 that was 
attached to the peptide.   
The importance of the Alexa488 in the study performed by Hirose et al. brings us 
back to an issue raised earlier; the mechanism used by CPPs to enter cells depends not 
only on the peptide but also other factors such as the size and physicochemical nature of 
its cargo [165].  For example, when TAT was fused to a protein, cellular uptake of the 
complex occurred through caveolae-mediated endocytosis [166].  When the peptide was 
conjugated to a fluorophore, however, uptake occurred through clathrin-mediated 
endocytosis [155].  Further, internalization of TAT/fusion protein complexes was largely 
limited to endocytosis, but TAT/small peptide complexes were internalized through both 
endocytosis and rapid, direct membrane translocation [167].   
Understanding cellular internalization means not only studying the CPP complex as 
a whole, but also considering the potential limitations of the different techniques used to 
study internalization.  One concern with many of the methods that have been used to 
study endocytosis of CPPs is the use of chemical inhibitors.  While chemical inhibitors 
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can be used to help understand the role of different endocytic uptake pathways in the 
internalization of CPPs, they also have a substantial impact on cell viability, thereby 
significantly affecting cells in ways that may make interpretation of the results difficult.  
Additionally, the performance of chemical inhibitors can be highly dependent on the cell 
line used.  Holm, Andaloussi, and Langel recently wrote a book chapter describing 
several methods (including fluorescence microscopy, HPLC, flow cytometry, 
spectrofluorometry, electron microscopy, and mass spectroscopy) for studying the uptake 
of CPPs, which can avoid the use of chemical inhibitors [168].  The authors provide a list 
of the advantages and drawbacks associated with the different methods and advocate for 
the use of more than one approach in order to avoid the negative aspects of the different 
methods. 
2.4 Applications using Cell-Penetrating Peptides 
CPPs have been used in a wide number of applications, ranging from simple cell 
culture transfection to the systemic delivery of therapeutics.  The focus here is to 
highlight a few of the many instances where CPPs have been used to deliver therapeutics, 
specifically nucleic acids, proteins, small molecules, and imaging agents.  Many of the 
examples of in vivo delivery are limited to small animals, and application of CPPs to 
human therapeutics has yet to prove effective.  CPPs enhance the general uptake of a 
therapeutic but in doing so reduce the specificity.  This loss of specificity is not only 
likely to impact efficacy but also safety. Much of the recent work has focused on using 
CPPs along with targeting ligands to improve delivery of a therapeutic.  As approaches to 
improve the targeted delivery of biomolecules are combined with CPPs, therapeutics may 
be delivered more efficiently, thereby greatly improving treatment outcomes. 
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Nucleic Acid Delivery 
One of the first biomedical applications of CPPs was delivery of nucleic acids into 
cells.  As previously mentioned, large hydrophilic molecules, such as nucleic acids, are 
generally inefficient at passing through the cell membrane.  To improve the delivery of 
nucleic acids, plasmid DNA has been complexed with cationic polymers or liposomes, 
which condense DNA into particles capable of entering cells through endocytosis.  
Similar to these polymeric and liposomal materials, cationic CPPs have also been used to 
condense plasmid DNA into small particles.  One of the first studies showing this was by 
Morris et al., who demonstrated that CPPs could be complexed with oligonucleotides 
through electrostatic attraction, which resulted in improved gene delivery [147].  Soon 
after, Transportan and pAntp were used to deliver peptide nucleic acid (PNA) by 
covalently linking the CPPs to the PNA [169].  These developments spurred additional 
investigations into using CPPs to deliver nucleic acids.  Recently, van Asbeck et al. 
sought to better understand what physicochemical and molecular factors most influence 
the successful delivery of CPP/siRNA complexes [170].  The authors discovered that 
CPP/siRNA complexes with the most negative zeta-potentials in serum were the most 
resistant to siRNA release over a 20 hour incubation period compared to less negatively 
charged complexes.  They also found that the zeta-potential of CPP/siRNA complexes in 
serum did not correlate with improved cellular association, which they explained could 
demonstrate the importance of serum proteins or CPP conformation on the ability of 
CPP/siRNA complexes to associate with the cell membrane. 
CPPs have also been coupled recently to other molecules to improve gene delivery 
after entry into the cell.  Favaro et al., for example, investigated combining TAT with a 
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fusion protein partially composed of the intracellular transport protein dynein light chain 
Rp3 for improving DNA delivery to the nucleus [171].  They found that using the CPP 
and the transport protein improved gene delivery by more than 7-fold compared to the 
transport protein alone.  Similarly, Lindberg et al. functionalized CPPs to not only 
penetrate the cell membrane but to also facilitate better intracellular trafficking by 
disrupting endolysosomes [172].  They delivered anti-microRNA oligonucleotides into 
cells by combining the endosomolytic agent trifluoromethylquinoline to the PepFect14 
CPP, producing a new CPP that the authors named PepFect15.  Compared to the 
PepFect14 complexes, PepFect15 produced a one-fold improvement in anti-microRNA 
delivery at the optimum CPP:oligonucleotide molar ratio.  
CPPs have been used also to enhance existing synthetic gene vectors in vivo.   
Hayashi et al. demonstrated that polyarginine functionalized lipoplexes efficiently 
silenced genes in a mouse liver [173].  An interesting and unexpected finding in 
subsequent work was that CPPs seemed to improve the long-term gene expression from 
vectors that normally only provide for very transient gene expression.  One example of 
this was a TAT-PEI vector that extended the gene expression period from about 1 month 
to nearly 7 months compared to TAT or PEI alone [174].  Another demonstration of this 
effect  by Yamano et al., showed that a TAT-modified liposome could be used to deliver 
a reporter gene with reasonable levels of expression for up to 7 months [175].  
One of the main limitations of gene vectors utilizing CPPs is low cell specificity.  A 
popular approach for improving synthetic gene vectors has been to incorporate targeting 
ligands with CPPs to better control cell-specific attachment.  Interestingly, synergism 
between the CPP and the targeting ligand has often been observed.  In a recent study, 
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Fang et al. found that the coupling of a vascular endothelial growth factor receptor-1 
targeting peptide to TAT internalized siRNA into cancer cells more readily than the CPP 
alone [176].  Improved and/or more selective gene delivery has also been reported with 
targeting ligands, such as mannose, folate, and RGD [177-179].  The same approach has 
also been applied to the delivery of siRNA using folate and penetratin [180]. The authors 
suggested that the multiple ligand approach increased the avidity for their siRNA 
nanoparticles toward folate expressing cancer cells.  
Interestingly, CPPs have also been demonstrated to transport nucleic acids to poorly 
accessible tissues such as the skin and brain.  Recently, Chen et al. used the SPACE 
peptide to deliver siRNA encapsulated in liposomes topically to the skin [181].   Other 
hard to reach tissues, such as the brain, have also become more accessible to therapeutics 
because of CPPs.  TAT-functionalized micelles were used to deliver a dual formulation 
of siRNA and camptothecin to a glioma through the nasal cavity in mice [182].  Similarly, 
a polyarginine CPP and a transferrin targeting ligand improved delivery of plasmid DNA 
encapsulated in a liposome to the brain [117].  
In addition to synthetic vectors, CPPs have been used also to improve viral gene 
delivery vectors.  Viral vectors are typically only efficient at gene delivery to cells that 
have the receptors that a virus needs for cell attachment and entry.  CPPs have been 
combined with viral vectors, however, to widen the range of cell types that viral vectors 
are able to infect.  By forming complexes through electrostatic attraction, several types of 
CPPs were found to improve the infectivity of an adenovirus gene vector, including cells 
poorly permissive to infection [114, 183].  Similarly, the ability of adeno-associated virus 
and baculovirus to deliver genes has also been improved using CPPs [184, 185].  
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Together, these studies demonstrate that viral vectors can be modified to deliver genes to 
a much wider range of targets, including various cancers and stem cells.   In one study, 
TAT was shown to increase the infectivity of an oncolytic adenovirus, which led to 
improved survival of tumor bearing mice [186].  Park et al. recently investigated the 
effects of oligomeric CPPs on adenoviral gene delivery to transduce stem cells [187].  
They found that tetramers of CPPs were better than CPP monomer at delivering 
adenovirus to mesenchymal stem cells.  
Some CPPs have been proven also to be effective antimicrobials and capable of 
penetrating into other types of non-mammalian cells. With the prevalence of multidrug 
resistant bacteria, the development of peptides to either act as antimicrobials or to deliver 
antimicrobial agents is an area of growing interest.  Bai et al. and Rajasekaran et al. 
delivered PNA into gram-negative bacteria, as well as intracellular bacteria strains using 
CPPs [188, 189].  Both CPP-PNA constructs inhibited microbial growth, demonstrating 
that gene silencing can be an effective approach to control bacteria.  Although many 
antimicrobial CPPs have been discovered, the mechanism behind their broad penetration 
ability remains an area of active investigation.  In one recent study, Rodriguez et al. 
found that the membrane potential is a key factor for cell entry of the model antimicrobial 
peptide Iztli-1 [190].  This provides a basis for further studies to understand why many 
CPPs can also act as antimicrobial peptides. 
Peptides, Proteins, and Enzymes 
As with gene delivery, proteins are typically unable to passively enter cells.  
Because many therapeutic targets are inside of cells, CPPs provide an ideal means for 
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intracellular delivery of the growing number of pharmaceutically relevant proteins [191].  
Early studies on the in vivo behavior of CPP conjugates of β-galactosidase coupled to 
TAT demonstrated that CPPs can facilitate the delivery of proteins into most cell types 
[192].  These prior successes have been built upon recently with CPPs transporting 
proteins into cells for treating specific diseases.  TAT has been used to deliver the herpes 
virus E2 protein to induce apoptosis in cervical cancer cells [193].  In another strategy to 
treat cancer, a polyarginine CPP was coupled with a tumor suppressing p53 protein to 
inhibit the growth of bladder cancer cells [194].  An interesting approach to build upon 
transporting anti-cancer proteins has been to use the tumor environment to modulate the 
function of CPPs, where by controlling the activity of the CPP, more cancer suppressing 
protein can be delivered to tumors.  Fei et al., for example, constructed a CPP that would 
be active in the acidic environment of tumor tissue by linking the MAP CPP to a pH-
sensitive peptide [195].  This approach improved the delivery of glutathione S-transferase 
to tumor cells in mice while reducing delivery of the protein to other tissues.  
CPPs have also been incorporated into gene editing strategies for treat disease.  
Specifically, CPPs are being used to deliver endonucleases into cells as an approach to 
remove disease-causing genes.  In one recent study, a CPP was used to deliver the Cas9 
protein and guide RNA for RNA-guided endonuclease gene editing [196]. Using this 
method, gene disruption was observed in several cell types.  In another study, Liu et al. 
used polyarginine to transport transcriptor activator-like effector endonuclease (TALEN) 
protein into cells [197].  The authors showed that the TALEN protein was able to 
specifically disrupt CCR5 and BMPR1A genes. 
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As described in several earlier examples, CPPs make it possible to transport 
enzymes into cells, which can lead to treatments for a wide range of diseases.  Enzymes 
that prevent oxidative damage are just one of several types of enzymes that are of interest 
for intracellular delivery, which can lead to preventative treatments against ischemic 
injury.  For example, TAT was combined with an enzyme called glyoxalase to prevent 
oxidative damage of neuronal cells [198].  In another example, antioxidant enzymes 
catalase and superoxide dismutase were delivered into cells using TAT, which protected 
the cells from oxidative stress [199, 200].  In an interesting approach to develop a long 
duration treatment for acute lymphoblastic leukemia, CPPs were used to deliver enzyme 
into red blood cells [48].  The enzyme L-asparaginase was delivered into functional red 
blood cells using the LMWP CPP.  This offers an innovative strategy to improve the 
circulation characteristics of proteins and many other types of molecules.  
CPPs have been used in several protein delivery applications in which the target cell 
type was non-mammalian, such as bacteria, fungus, and protozoa.  The few brief 
examples presented here demonstrate the broad penetrating ability of CPPs through cell 
membranes much different than that used to move proteins into human or mammal cells.  
Marchione et al., for example, demonstrated that the ZEBRA peptide CPP was able to 
deliver a green fluorescent protein into a pathogenic fungus [201].  This demonstrates the 
possibility that other types of protein therapeutics may be delivered into fungal cells.  
Keller et al. used several different types of CPPs to compare the ability of the CPP to 
deliver a protein (BSA or β Galactosidase) into a protozoa [202].  The authors noted that 
this approach could lead to new strategies to study protozoa and inhibit their growth.  
CPPs have also been used to deliver molecules into other animal cell types, which can 
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serve as important tools for advancing science as well as benefitting human health.  For 
example, Ma et al. used CPPs to deliver antigens into antigen presenting cells to provide 
fish immunity against bacterial infection [203], showing that CPPs can be an effective 
component in the formulation of novel vaccines. 
Small Molecules 
Similar to the large biomolecules discussed earlier, small hydrophilic molecules can 
also face difficulties in traversing the hydrophobic cell membrane.  In addition, 
conditions such as cancer, can also prevent effective transport of small molecules across 
the lipid bilayer.  CPPs have been shown to be a practical approach in improving the 
delivery of small-molecule cytotoxic drugs into cancer cells, while reducing the exposure 
of non-diseased tissues.  In one study, doxorubicin was coupled with polyarginine and 
found to inhibit tumor growth in vivo with fewer side effects compared to doxorubicin 
alone [204].  The authors noted that the cause behind the accumulation of the drug in the 
tumor was likely improved by the interaction of the cationic CPP with 
glycosaminoglycans.  Cai et al. used the hydrophobic PFV CPP to increase the delivery 
of a stealth liposome loaded with doxorubicin into cancer cells [140].  An interesting 
result in this study was that the hydrophobic CPP modified liposomes caused a reduction 
in tumor volume and resulted in fewer side effects compared to an unmodified liposome.   
Other strategies to improve small molecule drug delivery have focused on 
introducing new functionalities to CPPs for greater intracellular control of CPP/drug 
conjugates.  Lelle et al. investigated a CPP that was cross-linked with doxorubicin using a 
reducible disulfide linker [205].  The CPP conjugates were found to be cytotoxic toward 
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cancer cells with release of the doxorubicin into the cell cytosol. Nasrolahi et al. studied 
the anticancer activity of doxorubicin conjugated to a CPP in drug resistant cancer cells 
[206].  The authors observed more antiproliferative activity from the doxorubicin 
conjugated to the cyclic W(RW)4 CPP compared to the linear (RW)4 CPP.  Additionally, 
they found that the cyclic CPP doxorubicin conjugate had improved trafficking to the 
nucleus and reduced cellular efflux compared to free doxorubicin. 
Other types of small molecules have been delivered by CPPs as part of novel 
technologies ranging from neutron capture cancer therapy to methods for developing new 
cell preservation protocols.  Although the examples presented here are broad, they show 
that CPPs have wide utility beyond the delivery of well-studied molecules.  As part of an 
innovative cancer treatment, a CPP attached to a boron compound was delivered into 
malignant glioma cells for boron neutron capture cancer therapy [207].  The CPP 
combined with the boron compound was found to improve the killing of cancer cells 
compared to the boron compound without peptide.  CPPs are also being used as part of 
innovative strategies to preserve cells without cryopreservation.  The preservation agent 
trehalose was delivered into cells using a newly developed CPP, KRKRWHW, with the 
overall intent to investigate alternative cell preservation by desiccation [132].  The 
authors demonstrate that the novel CPP enters cells and that the inclusion of the 
preservation agent is non-toxic.  Another example of delivery of a small molecule using 
CPPs is the conjugation of the Tat CPP to a fluorescent label to photosensitize 
intracellular vesicles [208].  The label was further used as part of a strategy to damage the 
lipid membrane upon excitation of the label.  
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Novel chemotherapy approaches have focused on targeting the activity of 
anticancer drug-CPP conjugates to tumor tissue.  One approach that is growing in 
popularity is to make the CPP functional only when an enzyme common to the 
extracellular environment of tumors is present. Olson et al. demonstrated this with a CPP 
connected to an anionic polyion by a tumor matrix metalloproteinase cleavable linker, 
allowing the CPP to be activated in tumor tissue [209].  Xia et al. used this strategy to 
deliver paclitaxel with an activatable LMWP (ALMWP), protected by a polyanionic 
peptide that would only become active by tumor metalloproteinases removing the 
polyanion [210].  Another approach to producing activatable CPPs has been to use the 
acidity of the tumor environment to control the peptide activity.  Jin et al. made TAT 
inactive by converting the lysine amino groups of peptide to succinyl amides [211].  The 
group found that the acidity of tumor tissue can convert the modified peptide back to the 
active form of TAT, which caused better accumulation of peptide to the tumor.  
Imaging 
Imaging is of growing importance in the detection and monitoring of disease 
markers, which can lead to more effective disease management.  CPPs have been coupled 
with fluorophores, contrast agents, quantum dots, and other readily detectable molecules 
for visualizing the intracellular environment as well as specific cells.  In fact, 
fluorophores were one of the earliest cargos conjugated to CPPs as a means to study their 
activity.  Since then, CPPs have become important tools in biology for delivering 
fluorophores and quantum dots for intracellular detection.  Earlier studies, such as that by 
Delehanty et al., demonstrated that quantum dots could be transported across the lipid 
bilayer using polyarginine [212].  Subsequent work has utilized CPPs to deliver 
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fluorescent agents into cells for targeted intracellular delivery, which has also proven to 
be especially useful in cell biology.  Liu et al. was recently able to use the HR9 peptide to 
deliver quantum dots into cells without delivery to a lysosome or other organelles [213].  
In other cell biology applications, oxygen sensitive probes have been coupled to CPPs 
[214].  Using these probes allowed for the study of oxygen use inside cells.  New 
fluorescence strategies using CPPs have also been developed for better diagnosis of 
diseases over-expressing certain intracellular markers, such as the ubiquitin E3 ligase 
Smurf1 [215].  Researchers were able to observe Smurf1 binding through a CPP bearing 
a FITC label, a black hole quencher, and a Smurf1 binding peptide.  Changes in peptide 
confirmation with binding allowed for the group to observe the peptide and protein 
binding.  
CPPs have been designed to activate in certain tissue environments, and this has led 
to several exciting imaging applications.  For example, there is great interest in 
developing CPPs that will activate in tumors, which can in turn improve the detection of 
cancer cells and allow for real time imaging so that tumors may be removed more 
effectively.  CPP fluorophore conjugates have been designed to become active in tumors 
through an anionic domain that may be removed by tumor matrix metalloproteinases, 
effectively labeling tumor cells [216].  Efforts to better detect cancer metastasis through 
MRI and to improve the surgical removal of cancer have used activatable CPPs with 
fluorescent labels and gadolinium. [217, 218].  In another approach, an activatable CPP 
allowed for Savariar et al. to detect tumors in vivo [219].  In this study, a tumor specific 
protease disrupts the quenching of a label when the CPP is activated, which results in 
ratiometric detection of tumor metastasis.  This approach has also been used for detection 
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of thrombin activation in which a CPP was made active by thrombin, allowing the CPP to 
be internalized in nearby cells, which can lead to better treatment of atherosclerosis and 
strokes [220].  Another exciting approach has been the development of chemically 
sensitive linkers to produce other novel activatable CPPs.  This has led to new 
possibilities of detecting chemicals through imaging.  For example, Weinstain et al., 
developed a hydrogen peroxide activatable CPP to observe inflammation in the lungs of 
mice using FRET [221]. This enabled the group to detect oxidative stress both in vitro 
and in vivo, which has the potential to be a useful tool to monitor several types of 
diseases.  
2.5 Conclusions 
CPPs offer an exciting potential to transport many different types of therapeutic 
drugs across the cell membrane and into cellular compartments or the cell cytoplasm 
where a drug can be most effective.  While we do not entirely understand, nor can we 
necessarily predict how a CPP and its cargo will be transported into cells, we are 
developing the tools and knowledge necessary to harness their ability.  Already, there are 
hundreds of CPPs being explored for the delivery of therapeutic small molecules, 
peptides, proteins, nucleic acids, and imaging agents.  These studies are demonstrating 
success both in vitro and in vivo.   Successful transition from the laboratory setting to the 
clinic is only a matter of time.    
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EFFECT OF CATIONIC GRAFTED COPOLYMER STRUCTURE ON THE 
ENCAPSULATION OF BOVINE SERUM ALBUMIN 
 
3.1 Introduction 
One of the most promising methods to improve the controlled delivery of proteins 
is nano-encapsulation within biocompatible polymers. Although many methods of 
encapsulating proteins and biomolecules have been discovered, encapsulation using 
electrostatic interactions is one of the most practical. Encapsulation using electrostatics 
avoids the use of harsh solvents or direct modification of the protein, which are common 
with other protein encapsulation techniques and may lead to decreased protein function 
[222]. The formation of polyion complexes from oppositely charged polymers has been 
studied extensively, especially for gene delivery [20, 223-225]. In particular, cationic 
block copolymers of poly-L-lysine (PLL) and polyethylene glycol (PEG) have been 
widely studied as gene delivery vectors. PLL is a cationic polymer that has been used in 
many applications in which the polymer associates with negatively charged surfaces and 
molecules including nucleic acids and proteins [20, 226, 227]. PEG is another widely 
used polymer which has been found to improve the circulation characteristics and
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biocompatibility of many materials introduced in vivo [12]. Proteins and other particles 
coated with PEG are generally less immunogenic, less prone to renal clearance, and more 
resistant to proteolysis [228].  Additionally, coupling PEG onto cationic polymers has 
been found to reduce the susceptibility of the resulting complex to aggregation [223, 
229]. Charged polymers and copolymers have also found growing applicability in 
encapsulation of protein-based therapeutics [21, 226, 230-233], where protein polyion 
complexation has already been demonstrated to be an effective method to encapsulate 
proteins [27, 231, 234-240]. Additionally, several enzymes complexed with polyions 
have been shown to retain catalytic activity following encapsulation [231, 234, 241, 242].  
Although the characteristics of charged block copolymers that lead to 
encapsulation of proteins into micelles have been well studied, there have been relatively 
few investigations into what design parameters are important for the encapsulation of 
proteins by charged grafted copolymers. The purpose of the present work was to 
investigate how variations in grafted cationic copolymer architecture affect protein 
encapsulation and stability.  First, nine different PLL-g-PEG copolymers were 
synthesized to investigate the effect of PEG:PLL grafting ratio and PLL molecular weight 
on protein encapsulation. Using BSA as a model protein, we saw that the properties of 
the copolymer affected protein encapsulation and nanoparticle stability while having no 
detrimental impact on protein function. Moreover, the protein remained functional toward 
small molecules as a NP, demonstrating that release of the protein was not necessary for 
protein-small molecule interactions. Together, the results of this study provide insight 
into how grafted copolymer architecture affects the properties of self-assembled protein 
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NPs and guides improvements toward the use of grafted cationic copolymers for protein 
delivery.  
3.2 Materials and Methods 
 
Bovine serum albumin (BSA), poly-L-lysine-HBr (PLL) with molecular weights 
4-15 kDa, 15-30 kDa, and 30-70 kDa, p-nitrophenyl caprylate, and chymotrypsin from 
bovine pancreas were purchased from Sigma Aldrich (St. Louis, MO). Polyethylene 
glycol with 2 and 5 kDa molecular weights and functionalized with a carboxymethyl 
succinimidyl ester (mPEG-NHS) were purchased from Creative PEGworks. 
Glutaraldehyde (50% (w/w)), acrylamide/bisacrylamide (37.5:1) and other 
polyacrylamide gel casting and running materials were purchased from Fisher Scientific 
(Pittsburgh, PA). DQ Green BSA was purchased from Life Technologies (Grand Island, 
NY). 
3.2.1 PLL-g-PEG Grafted Copolymer Synthesis 
PLL-g-PEG was synthesized using the succinimidyl ester leaving group on the 
PEG to conjugate to the primary amine groups of the PLL. Various masses of 2 kDa and 
5 kDa mPEG-NHS (a 50/50 mixture (w/w)) were added to 15 mg of 4-15, 15-30, and 30-
70 kDa PLL-HBr dissolved in 200 µL of phosphate buffered saline (PBS). The amounts 
of PEG required to form each copolymer were pre-determined experimentally by trial and 
error (data not shown). For 4-15 kDa PLL (defined as “low molecular weight”), 28, 40, 
and 48 mg of a 50/50 (w/w) mixture of 2 and 5 kDa PEG were added to the dissolved 
PLL to produce the grafting ratios 2, 10, and 20, respectively. For 15-30 kDa PLL 
(defined as “medium molecular weight”), 4, 40, and 48 mg of a 50/50 (w/w) mixture of 2 
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and 5 kDa PEG were added to the dissolved PLL to produce the grafting ratios 2, 10, and 
20. For 30-70 kDa PLL ( defined as “high molecular weight”), 2, 10, and 18 mg of a 
50/50 (w/w) mixture of 2 and 5 kDa PEG were added to the dissolved PLL to produce the 
grafting ratios 2, 10, and 20, respectively. The mixtures were allowed to react for 2 hours 
before being washed with ultrapure water in a 10 kDa centrifugal concentrator. After 3 
washes, each grafted copolymer was lyophilized and stored at -20°C.  
The grafting ratio of each PLL-g-PEG was determined using proton nuclear 
magnetic resonance spectroscopy (1H NMR). Each grafting ratio was approximated as a 
distribution of PLL molecular weights was used to synthesize the grafted copolymer. 
Lyophilized polymer was dissolved in D2O, and 1H NMR spectroscopy was performed 
using a Bruker Avance INOVA 400 MHz spectrometer. The grafting ratio, or PEG chains 
per PLL chain, was determined by integrating the PLL and PEG peaks at 4.3 ppm and 3.7 
ppm, respectively. A summary of the copolymers produced is shown in Table 2.1. 
3.2.2 BSA Nanoparticle Synthesis 
BSA nanoparticles (NPs) were formed through the electrostatic interaction of the 
cationic backbone of the PLL-g-PEG copolymer and negatively charged BSA. BSA was 
prepared by dissolving lyophilized BSA in PBS to a concentration of 1 mg/mL. The BSA 
was then filtered through a 0.2 µm syringe filter to remove larger aggregates. Then the 
filtered protein concentration was determined by measuring the absorbance of the sample 
at 280 nm. The filtered BSA solution was further diluted in PBS to produce a 0.27 
mg/mL BSA solution.  
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PLL-g-PEG copolymer was dissolved in PBS at varying concentrations in order 
to add the same volume of polymer solution to BSA while varying the copolymer-to-
protein mass ratio (C:P ratio) when forming NPs. Copolymer-to-protein mass ratios of 
1:1, 2:1, 3:1, 7:1, 10:1, and 14:1 were produced to study the effect of copolymer 
concentration on protein encapsulation. NPs were formed by adding 7.5 µL of copolymer 
solution to 25 µL of BSA at 0.27 mg/mL under gentle vortexing and allowing the 
solution to incubate for 1 hour at room temperature, similar to the approach of Gaydess 
and coworkers [241].  
Following NP formation, NPs were stabilized using glutaraldehyde to cross-link 
amino groups [27]. From a 50% stock solution, glutaraldehyde was diluted in PBS to 
produce a 0.025% glutaraldehyde solution. After 1 hour of NP formation, 5 µL of 
0.025% glutaraldehyde was added to the NP samples followed by incubation for 3 hours 
at room temperature. The cross-linked NPs were either used immediately or stored at 
4°C. 
3.2.3 SEM Analysis of BSA Nanoparticles 
The morphology and size of the BSA NPs were analyzed with an FEI Quanta 600 
scanning electron microscope (SEM) at an accelerating voltage of 20 kV. Samples of 
BSA were encapsulated using a PLL-g-PEG (15-30 kDa), grafting ratio 10, with a C:P 
ratio of 7:1, and were deposited onto aluminum SEM stubs using a drop-casting method 
and allowed to air-dry at room temperature for 24 hours. Dried samples were sputter-
coated with gold using a Cressington 108 sputter coater. Average sample size and size 
43 
 
distribution of the NPs were determined by analyzing 117 particles using ImageJ image 
analysis software. 
3.2.4 TEM Analysis of BSA Nanoparticles 
The internal structure of BSA NPs was analyzed using transmission electron 
microscopy (TEM). BSA was encapsulated using PLL-g-PEG (15-30 kDa) with a 
grafting ratio of 10 and a C:P ratio of 7:1 as described in the NP synthesis section. 
Following NP synthesis, 30 µL of NPs were placed on a formvar-carbon coated grid and 
allowed to air-dry at room temperature overnight. The sample was then negatively 
stained with 30 µL of phosphotungstic acid (pH 7.4), which was wicked off the grid after 
1 minute using filter paper. The sample was allowed to dry for 2 hours before observation 
with a JEOL JEM-2100 electron microscope. 
3.2.5 Gel Migration Assay and Encapsulation Efficiency 
The extent of BSA encapsulation into NPs was determined using a non-reducing 
gel retardation assay. Samples containing approximately 2 µg of BSA, BSA exposed to 
glutaraldehyde, or BSA NPs were loaded onto 8% SDS-PAGE gels. The samples were 
not boiled and sample buffer (61% (v/v) DI water, 13% (v/v) 0.5 M Tris-HCl pH 6.8, 
26% (v/v) glycerol, 2.1% (w/v) SDS, and 0.01% (w/v) bromophenol blue) did not include 
a reducing agent. SDS-PAGE gels were run at 200 V on a Bio-Rad tetracell mini gel 
electrophoresis apparatus until the dye front reached the bottom of the gel. The running 
buffer (1.5 g/L Tris Base and 7.2 g/L glycine) did not contain SDS. The SDS-PAGE gels 
were stained with Coomassie G-250 before imaging. The relative band intensity of the 
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non-encapsulated BSA was compared to the BSA with which copolymer was added to 
determine the extent of protein encapsulation.  
3.2.6 Nanoparticle Size and ζ-Potential 
The hydrodynamic diameter and surface charge of NPs were measured using a 
ZetaPALS Brookhaven Instruments Corporation ζ-potential analyzer. Prior to the 
measurements, samples were diluted in PBS to a total volume of 750 µL or 1.5 mL and 
passed through a 0.2 µm syringe filter directly into a disposable cuvette to remove dust 
from the sample. Dynamic light scattering (DLS) was used to determine the NP 
hydrodynamic diameter. A total of 5 measurements, lasting 2 minutes per measurement at 
a 90° angle were used to determine the average size of the NPs by intensity. The ζ-
potential, determined by using phase analysis light scattering (PALS), was calculated 
from the electrophoretic mobility using Smoluchowski’s equation [243]. A total of 10 
measurements, each lasting 30 seconds, were used to determine the average ζ-potential of 
the NPs. 
3.2.7 Retention of Protein Esterolytic Activity 
The effect of encapsulation on protein function was determined by measuring the 
cleavage of a p-nitrophenyl ester by BSA [244].  Based on the method used by Córdova 
et al., the ester binding and hydrolysis of encapsulated BSA was measured by monitoring 
the release of p-nitrophenol spectrophotometrically [245]. To measure esterolytic 
activity, 5 µL of 6 mM p-nitrophenyl caprylate in isopropanol was added to 100 µL of 
either non-encapsulated BSA or NPs, and the mixture was allowed to incubate 20 hours 
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at 37°C before absorbance measurements were taken at 410 nm on a Packard 
Spectracount plate reader. 
3.2.8 Stability of NPs Against Polyanions 
The stability of NPs against heparin, a polyanion with a high charge density, was 
evaluated using the gel retardation assay described above. NPs were produced from low, 
medium, and high molecular weight (all 10:1 grafting ratio) copolymers at 1:1, 7:1, and 
14:1 C:P ratios. The NPs were then incubated with PBS (control) or heparin in PBS at 0.1 
mg/mL and 1 mg/mL for 24 hours at 37°C before PAGE. 
3.2.9 Stability of NPs Against Protease Degradation 
NPs were prepared following the method described above to encapsulate DQ 
Green BSA, a form of BSA that is so heavily labeled with BODIPY dye that the 
fluorescence is self-quenched. When degraded by protease, this quenching is relieved as 
fragments are released, and thus the protein degradation can be measured 
fluorometrically [246]. For these assays, DQ Green BSA NPs were prepared from low 
molecular weight grafting ratio 10, medium molecular weight grafting ratio 10, and high 
molecular weight grafting ratio 10 copolymers and encapsulated at 1:1, 7:1, and 14:1 C:P 
ratios. The NPs were incubated with chymotrypsin at 0.25 mg/mL at 37°C, and the 
fluorescence was measured over time (Exc: 485 nm Em: 535 nm) using a Beckman 





3.2.10 Statistical Analysis 
Statistical analysis was performed in Microsoft Excel using one-way analysis of 
variance (ANOVA) and pair-wise comparisons by Tukey’s post hoc test. Data from the 
protease degradation study were fitted using a one site saturation model in SigmaPlot.  
3.3 Results and Discussion 
3.3.1 PLL-g-PEG Synthesis 
 
Figure 3.5. Synthesis of PLL-g-PEG Copolymer and Synthesis of BSA NPs. mPEG-NHS (2 and 5 kDa) 
was grafted onto 4-15 kDa, 15-30 kDa, and 30-70 kDa PLL. Three different grafting ratios (approximately 
2, 10, and 20) were produced by varying the mass of PEG added to each PLL. BSA NPs were produced 
through self-assembly of the negatively charged BSA protein and the cationic PLL-g-PEG copolymer. 
After one hour of assembly in phosphate buffered saline, the NPs were cross-linked using 0.003% 
glutaraldehyde. 
A library of nine PLL-g-PEG copolymers was synthesized to study the effect of 
PLL molecular weight and PEG grafting ratio on BSA encapsulation. A mixture of PEG 
molecular weights were used for the copolymers because a future aim of our work is to 
develop copolymers functionalized with two different types of ligands at different 
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distances away from the PLL backbone. The synthesis of PLL-g-PEG was performed as 
illustrated in Figure 3.1, with greater quantities of PEG added to the PLL to produce 
higher grafting ratios. The approximate number of PEG chains grafted onto each PLL 
chain was determined using 1H NMR. The grafting ratio calculation and 1H NMR 
spectrum may be found as supplementary material (Section S1 of Appendix).  A 
summary of the library used and the results obtained is presented in Table 3.1. All of the 
copolymers produced had PEG grafting ratios within three PEG chains of the targeted 
grafting ratio. By producing this nine-copolymer library, we could then proceed to better 
understand the effect of PEG grafting and PLL molecular weight on association of the 
grafted copolymer with BSA. 
Table 3.1. Summary of PLL-g-PEG Library Produced for BSA Encapsulation. The observed grafting 
ratios were measured using 1H NMR. 
Polymer 
Nomenclature PLL Molecular Weight 
Targeted PEG 
Grafting Ratio 
Observed PEG Grafting 
Ratio (±3 of Targeted 
Grafting Ratio) 
 LMW 2  Low (4-15 kDa) 2 4.6   
   LMW 10  Low (4-15 kDa) 10 7.9 
   LMW 20  Low (4-15 kDa) 20 23.5 
  MMW 2  Medium (15-30 kDa) 2 4.6   
    MMW 10  Medium (15-30 kDa) 10 11.0 
    MMW 20  Medium (15-30 kDa) 20 19.1 
 HMW 2  High (30-70 kDa) 2 3.6   
   HMW 10  High (30-70 kDa) 10 11.2 




3.3.2 BSA Encapsulation Efficiency 
To determine the extent of BSA encapsulation, NPs assembled from the 
copolymer library were characterized by gel retardation assays. Results showed that the 
BSA exposed to glutaraldehyde migrated slightly faster compared to unmodified BSA 
(Fig. 3.2, lane 2 of each panel). At low glutaraldehyde and protein concentrations, 
intramolecular cross-linking of the protein is more likely to occur than intermolecular 
cross-linking [247]. The results of Figure 3.2 indicate that glutaraldehyde did not cause 
intermolecular cross-linking of BSA as no additional higher molecular weight aggregates 
were observed following treatment. The slightly faster migration of BSA through the gel 
is likely a result of intramolecular cross-linking of the BSA that hindered the ability 
sodium dodecyl sulfate (SDS) to fully denature the protein. Upon the addition of 
copolymer, a combination of cross-linking between copolymer chains and between the 
copolymer and protein occurred. At the 1:1 C:P ratio, some heterogeneous retardation of 
BSA mobility (“smearing”) was apparent on the gel, with a concomitant decrease in band 
intensity or spreading of the band for the free protein (Fig. 3.2, lane 3 of each panel). In 
cases at which the free protein band widened at a 1:1 C:P ratio, this appears to be due to a 
portion of the BSA becoming cross-linked by glutaraldehyde, producing a free protein 
band that appears to be a mixture of what is observed in lanes 1 and 2. The migration of 
BSA decreased as the C:P ratio was increased above 1:1, with markedly reduced BSA 
migration being apparent at higher C:P ratios for all of the copolymers. At C:P ratios 
between 3:1 and 7:1, high molecular weight copolymers retarded the mobility of 
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effectively all of the BSA molecules (Fig. 3.2, row 1, lane 6), indicating that 
encapsulation or loading of the protein into the NPs was 100%.  




















Figure 3.2. Encapsulation Efficiency of BSA with high, medium, and low molecular weight PLL-g-
PEG copolymers with grafting ratios 2, 10, and 20. Each column corresponds to the mPEG grafting ratio 
for the copolymer. The row corresponds to the PLL molecular weight, with high, medium, and low being 
30-70 kDa, 15-30 kDa, and 4-15 kDa PLL, respectively. In each panel, the sample in each lane is as 
follows with the NP lanes differentiated by C:P ratio: Lane 1: BSA; Lane 2: BSA incubated with 
glutaraldehyde; Lane 3 1:1 NP; Lane 4: 2:1 NP; Lane 5: 3:1 NP; Lane 6: 7:1 NP; Lane 7: 10:1 NP; Lane 8: 
14:1 NP. The extent of BSA encapsulation was determined by comparing the relative band density of the 




When the C:P ratio was increased even further, all of the protein was retained in the 
stacking gel, which also suggested complete loading of the protein into NPs. These 
results demonstrated a direct relationship between C:P ratios and BSA encapsulation. 
The molecular weight of the copolymer PLL chain also had a substantial effect on 
protein encapsulation. For most of the copolymers, higher C:P ratios were required to 
effectively encapsulate BSA with the LMW and MMW copolymers compared to the 
HMW copolymers. For the MMW copolymers, a C:P ratio of at least 7:1 was required for 
protein migration to be fully retarded. Similarly, the LMW copolymers were generally 
the least effective in retarding migration.  The LMW 2 copolymer was one exception 
with this copolymer associating effectively with BSA. Due to a higher number of 
copolymer chains relative to the MMW 2 and HMW 2, the LMW 2 copolymer may have 
been able to form glutaraldehyde crosslinks between multiple copolymer chains better 
than the other copolymers, leading to more efficient encapsulation. Generally though, the 
higher the molecular weight of the PLL portion of the copolymer, the more efficiently the 
copolymer associates with the protein. 
 The larger molecular weight PLL copolymers encapsulated BSA at lower C:P 
ratios compared to the smaller molecular weight copolymers. This is similar to higher 
PLL molecular weights improving DNA condensation through improved ion pairing 
[248, 249]. This decrease in C:P ratio required for efficient encapsulation was likely a 
result of the differences in the electrostatic charge of the copolymers. Because the grafted 
copolymer was synthesized by conjugating PEG to the amine groups that give the PLL 
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polymer its positive charge, higher grafting ratios result in copolymers with fewer amine 
groups and a lower charge.  Similarly, for a fixed grafting ratio (mol:mol), high 
molecular weight PLL has a greater number of positively charged amine groups per PLL 
chain than the medium or low molecular weight PLL. This leaves the high molecular 
weight copolymers with more charge overall, and enables them to more easily associate 
with the BSA. In contrast, medium and low molecular weight copolymers have more 
PLL amine groups substituted by PEG. Thus, the low and medium molecular weight 
copolymers have had more of the PLL charge neutralized, leading to the observed higher 
quantities of copolymer needed to effectively associate with the BSA. Although using 
high amounts of copolymer to encapsulate a protein is not necessarily desirable for most 
efficient use of the copolymer, using copolymers with a large number of PEG chains is 
likely to be beneficial in vivo for reducing serum protein opsonization and clearance 
[250]. Therefore, there is a need to balance efficient encapsulation with sufficient 
PEGylation.  
Together, the results of Figure 3.2 indicate that copolymer molecular weight, C:P 
ratio, and grafting ratio all impact the encapsulation of BSA. For a fixed PLL molecular 
weight, increasing the amount of grafted PEG generally led to a decrease in the amount 
of protein encapsulated for a given C:P ratio. PEG grafting onto PLL, however, is 
important in the formation of micelle-like nanoparticles rather than large aggregates 
commonly formed from cationic polymers and negatively charged biomolecules [22, 
248]. To limit the number of particles further characterized, the PLL molecular weight 
and the C:P ratio (1:1, 7:1, and 14:1) were varied while the grafting ratio was held 
constant (10:1) for the remainder of the study.  
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3.3.3 NP Structure and Morphology 
In addition to the gel retardation assay, electron microscopy was used to confirm 
the formation of BSA NPs. BSA NPs were observed in Figures 3.3 and 3.4, using 
scanning (SEM) and transmission electron microscopy (TEM). SEM results for the 
encapsulation of BSA with MMW 10 and a C:P ratio of 7:1 show NPs that were typically 
ellipsoids but often had irregular morphologies, Figure 3.3. The size of the BSA NPs 
based on SEM ranged from about 20 – 100 nm, with an average of 50 nm (Figure 3.4). 
This was similar to the diameter of other protein polyion complexes that have been 
previously characterized with sizes under 100 nm [234, 241]. 
TEM was used to determine the internal structure of the NPs. The TEM 
micrograph in Figure 3.3 (Panel B) shows NPs produced from MMW 10 with a C:P ratio 
of 7:1 that ranged from approximately 20-100 nm in diameter. The interior of the NPs 
had a punctate appearance with a bright outline. The white outline surrounding each 
particle is consistent with the formation of a PEG corona, which is similar to that 
observed around other PEGylated NPs [251]. This contrasts with BSA that had been 
encapsulated with MMW PLL alone (Panel C) in which only a thin dark outline 
surrounded these particles, which were typically much larger than 100 nm. The layering 
of the light outer region over the punctate interior suggests that the PEGylated NPs had a 
core/shell structure. A core-shell structure is consistent with the observations of others 
that have produced polyion complexes [225, 252]. This is likely due to steric effects of 
the hydrophilic PEG favoring placement at the outer surface of the particle and the 
cationic component of the polymer favoring association with negatively charged 




Figure 3.3. Electron Microscopy of BSA NPs. The formation of BSA NPs was confirmed using SEM (A) 
and TEM (B). A TEM micrograph of BSA complexed with unPEGylated  15-30 kDa PLL was used as a 
control (C). The NPs in the above micrographs were produced using BSA and medium molecular weight 
PLL, PEG grafting ratio 10 with a 7:1 C:P ratio. The SEM and TEM scale bar lengths are 100 nm. 
 
Figure 3.4. NP Size Distribution. The size distribution of MMW 10 7:1 NP was determined from multiple 
the SEM micrographs with a representative one shown above (A). The scale bar length is 500 nm. To 
determine the size distribution, NPs were treated as spherical particles and the particle diameter was 
determined using Image J (B). The size distribution was determined from 117 NPs. The mean particle size 

























3.3.4 NP Physicochemical Properties 
Dynamic light scattering and PALS were used to determine the size and ζ-
potential of NPs formed from LMW 10, MMW 10, and HMW 10 copolymers at a 7:1 
C:P ratio (Table 3.2). The particle size, when measured using dynamic light scattering, 
indicated that NPs were approximately 20 nm in diameter for all three copolymers tested. 
Light scattering indicated that a distribution of NPs was formed, with some NPs slightly 
smaller than 20 nm and other NPs up to 100 nm in diameter (data not shown).  All three 
techniques indicate that a distribution of nanoparticle sizes was formed with a size 
ranging from approximately 20-100 nm. The low contrast of the NPs when observed 
under SEM favors larger particles to be more easily observed and differentiated from the 
background, which may skew the average particle size. Additionally, differences in 
sample preparation may contribute to the differences observed.  
Table 3.2 Physicochemical Characterization of BSA NPs. The average hydrodynamic diameter for 
LMW 10, MMW 10, and HMW 10 7:1 NPs was determined using dynamic light scattering. The ζ-potential 
or surface charge of the NPs was measured using Phase Analysis Light Scattering (PALS). The results 
shown are the mean and standard deviation of three replicates. 
 LMW 10 NP MMW 10 NP HMW 10 NP 
Diameter (nm)   24±0.6  18.8±3.4 23.5±3.2 
ζ-Potential (mV) -2.3±4.3 -12.4±1.2   5.3±2.5 
 
To learn how the copolymers affected the NP surface charge, the ζ-potential, a 
measurement of surface charge, was determined for NPs formed from LMW 10, MMW 
10, and HMW 10.  In contrast to particle size, each of the three copolymers produced 
NPs with different ζ-potentials. The NPs produced from the HMW 10 copolymer were 
positive in charge. This was expected as the HMW 10 has the fewest number of 
55 
 
positively charged amine groups substituted by PEG of the three copolymers tested, 
resulting in particles with a positive charge.  
NPs produced from the MMW 10 copolymer had the most negative charge of the 
three measured. A negative surface charge may suggest the presence of protein as well as 
PEG near the particle surface. Given there was a small amount of free BSA at this C:P 
ratio based on the gel retardation assay, it is possible that some free protein was 
associated with the NP surface which may have resulted in the non-linear relationship 
between the ζ-potential and the copolymer molecular weight. Even though a small 
amount of free protein was observed on the PAGE gels for the other two copolymers, it is 
conceivable that the charge density of the MMW 10 copolymer and the extent that the 
polymer was PEGylated made this effect more prevalent compared to the other two 
copolymers. The lower charge density of the MMW 10 copolymer, relative to the HMW 
10 copolymer, may have allowed for a combination of PEG and small quantities of 
protein to be located at the particle surface.  
The LMW 10 NPs had a charge close near neutral, which was expected from NP 
produced from the most PEGylated of the three copolymers because PEG is a neutrally 
charged polymer. The more highly PEGylated LMW 10 NPs, however, may prevent any 
free protein adsorption to the NP surface from occurring The higher degree of 
PEGylation may cause the PEG to become densely packed and prevent any protein 
binding near the particle surface. Overall, the ζ-potential of the NPs tested were near 0 
mV, which could be a positive characteristic for minimizing non-specific interactions 




3.3.5 Retention of Protein Esterolytic Activity 
To examine the effect of encapsulation on protein function, the esterolytic activity 
of BSA toward a p-nitrophenyl ester was measured. Albumin can bind to and hydrolyze 
ester substrates [253]. Results showed that the ability of BSA to bind and cleave a p-
nitrophenyl ester was not adversely affected by encapsulation or cross-linking (Fig. 3.5); 
esterolytic activity of the encapsulated BSA was similar to that of the non-encapsulated 
BSA. When BSA was encapsulated with the medium or high molecular weight 
copolymers, the activity of the protein was slightly higher than the non-encapsulated 
protein. Although significant compared to the free protein, the C:P ratio had a relatively 
minimal effect on protein activity within individual copolymer PLL molecular weights, 
with higher C:P ratio NPs showing slightly higher esterolytic activity. 
 
Figure 3.5. Retention of BSA Esterolytic Activity. BSA catalytic activity was measured by monitoring 
the hydrolysis of p-nitrophenyl caprylate with absorbance values taken at 410 nm after approximately 20 
hours. Activity was normalized to that of the non-encapsulated BSA. The data is the mean and standard 























































































Our finding that encapsulation slightly enhances BSA esterolytic activity is 
consistent with previous observations that the catalytic activity of lysozyme toward a p-
nitrophenol ester was enhanced following encapsulation with a polyaspartate-PEG 
copolymer [254]. Those authors suggested that the enhanced activity was likely due to 
accumulation of the hydrophobic substrate in the micelle, leading to a higher 
concentration of substrate near the protein than in the surroundings of the micelle. This 
explanation is also consistent with the observation that increasing the C:P ratio led to an 
increase in protein catalytic activity. Others have similarly seen an increase in apparent 
enzyme activity following encapsulation of catalase into polyion complex micelles, 
which could also be attributed to an increase in substrate concentration within the micelle 
[234]. 
3.3.6 Stability of NPs Against Polyanions 
Many serum proteins and heparin sulfate proteoglycans have an overall negative 
charge, which may cause dissociation of polyion complexes in vivo. To learn how 
susceptible the copolymer NPs are to negatively charged molecules the stability of LMW 
10, MMW 10, and HMW 10 NPs to polyanions was evaluated using heparin (Figure 3.6). 
Generally, the NPs were resistant to the effects of heparin, with most of the protein 
remained associated with the NPs after co-incubation. Although very little dissociation of 
the encapsulated protein was observed, increasing heparin concentration led to protein 
release from the NP. The LMW10 copolymer had the lowest stability against polyanions, 
as more BSA was released from these NPs compared to MMW10 and HMW10 
copolymers. This may be due to the low molecular weight copolymer having the lowest 
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charge density among the three copolymers tested. The low molecular weight copolymers 
have the fewest cationic amine groups per copolymer chain making them more 
susceptible to disassociation by a polyanion. For all three copolymers tested, the 7:1 C:P 
ratio showed the greatest stability against heparin at 1 mg/ml compared to the 1:1 and 
14:1 ratios. At the 1:1 C:P ratio, the protein is not fully encapsulated, making the amount 
of free protein detected in the presence of heparin already high. The 14:1 C:P ratio in 
particular was among the least stable of the NPs.  NPs with high C:P ratios (14:1) may be 
more susceptible to dissociation by polyanions due to less organization between 
copolymer and BSA layers, reducing the efficiency of glutaraldehyde cross-linking. At 
the 7:1 C:P ratio, glutaraldehyde cross-linking of NPs completely encapsulating the 
protein is most efficient relative to the 1:1 and 14:1 C:P ratios. 
LMW 10 MMW 10 HMW 10 
   
 
Figure 3.6. NP Polyion Stability after Incubation with Heparin. NPs were incubated with heparin at 
37°C for 1 day. Lane 1: BSA; Lane 2: 1:1 NP, 0 mg/ml heparin; Lane 3: 1:1 NP 0.1 mg/ml heparin; Lane 4: 
1:1 NP 1 mg/ml heparin, Lane 5: 7:1 NP 0 mg/ml heparin; Lane 6: 7:1 NP 0.1 mg/ml heparin; Lane 7: 7:1 
NP 1 mg/ml heparin; Lane 8: 14:1 NP 0 mg/ml heparin; Lane 9: 14:1 NP 0.1 mg/ml heparin; Lane 10: 14:1 
NP 1 mg/ml heparin. 
3.3.7 Stability of NPs Against Proteolysis 
Proteolysis is a major cause of inactivation of pharmaceutically relevant proteins 
in clinical settings.  In order to determine if our NP could protect BSA from proteolysis, 
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the effect of encapsulation was evaluated using chymotrypsin as a model protease [255, 
256]. These assays used BSA that was heavily labeled with a self-quenching BODIPY 
fluorescent dye, with degradation of the BSA being observed as an increase in 
fluorescence [246]. Results showed that the non-encapsulated BSA was rapidly degraded 
by chymotrypsin, as indicated by the increase in fluorescence over the first 24 hours of 
the study (Fig. 3.7, filled circles). Cross-linking the BSA with glutaraldehyde reduced the 
maximal degree of proteolysis (Fig 3.7, open circles). Encapsulation provided additional 
protection from the protease, with the BSA NPs releasing only 25% of the fluorescence 
relative to the free protein after 48 hours of exposure to chymotrypsin. Although the 
extent of chymotrypsin protection was found to be relatively similar for all of the 
copolymers, the high molecular weight copolymer appeared to offer slightly lesser 
protection. Additionally, the C:P ratio had little effect on protecting against BSA 
degradation.  These results indicated that glutaraldehyde cross-linking and copolymer 
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Figure 3.7. Stability of NPs to Protease Degradation. DQ Green BSA was encapsulated to form LMW 
10, MMW 10, and HMW 10 NPs at 1:1, 7:1, and 14:1 C:P ratios. NPs were exposed to chymotrypsin (0.25 
mg/ml) at 37°C over 48 hours. Proteolysis was monitored fluorometrically. Each data point represents the 
mean of three replicates and the error bars represent the standard deviation. 
Glutaraldehyde cross-linking as well as other cross-linking strategies have been 
commonly used to enhance the stability of proteins and polyion complexes against 
proteases and other forms of degradation [31, 247]. The increased stability of proteins 
modified by cross-linkers, such as glutaraldehyde, has been attributed to an increase in 
protein rigidity due to intramolecular and/or intermolecular cross-linking between 
proteins and polymers [257]. Chymotrypsin has preferential activity at aromatic amino 
acid residues [258]. Intramolecular cross-linking of BSA likely affected conformational 
changes of the protein and reduced the access of chymotrypsin to the hydrophobic 
residues the protease preferentially cleaves.  
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Similarly, the formation of rigid, intermolecular cross-links by glutaraldehyde 
between copolymer chains as well as between the copolymer and BSA could be expected 
to further prevent access of the chymotrypsin to the protein. Additionally, PEGylation of 
the copolymers can sterically hinder interactions between the chymotrypsin and the 
protein NPs. Similar results were observed by others who found that encapsulation of 
DNA into polyplexes by PLL-g-PEG reduced the susceptibility of the DNA to 
degradation by nucleases [10, 259]. Protection as a result of PEGylation is consistent 
with the observation that the HMW 10 copolymer provided the least protection against 
proteolysis of the three NPs. The HMW 10 copolymer had the fewest PEG chains 
capable of protecting the protein compared to the low and medium molecular weight 
copolymers (at a given C:P ratio).  
3.4 Conclusions 
Protein encapsulation into polyion complexes is a promising approach to improve 
protein delivery. Very little systematic investigation, however, has been done into how 
characteristics of grafted cationic copolymers affect the encapsulation and stability of 
protein polyion complexes. The approach taken in this study found that PLL molecular 
weight, PEG grafting ratio, and C:P ratio all affect encapsulation of BSA. Protein 
catalytic activity was retained through the encapsulation process and even showed 
increased levels of activity at high C:P ratios for the medium and high molecular weight 
copolymers. Over a constant grafting ratio of 10, the medium and high molecular weight 
copolymers showed more resistance to polyanions than the low molecular weight 
copolymer. The low and medium molecular weight copolymer provided more protection 
for the protein from proteolysis compared to the high molecular weight copolymer. 
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Overall, a medium molecular weight PLL backbone with a grafting ratio of 
approximately 10 PEG:PLL effectively balanced protein association with the copolymer 
and NP stability. Future studies that focus on protein delivery under physiological 
conditions will undoubtedly provide additional framework for the design of an efficient 
protein delivery system. 
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ALBUMIN DENATURATION IMPACTS MACROPHAGE UPTAKE OF CPP 
FUNCTIONALIZED PLL-G-PEG/GOX COMPLEXES. 
 
4.1 Introduction 
Since the discovery of the first cell-penetrating peptide (CPP) derived from the 
HIV Tat protein, CPPs have garnered significant interest as vehicles for delivering 
therapeutic agents into the intracellular space [109, 260]. While CPPs are capable of 
transporting themselves across the membrane of most cell types, they are also capable of 
transporting many types of cargo into the cell interior, including small molecule drugs, 
dyes, quantum dots, proteins, viruses, and many types of nanoparticles that would 
otherwise be unable to reach the cell interior [49]. Many types of CPPs contain several 
arginine residues, making them highly cationic in physiological conditions [261]. This 
cationic property is believed to drive the binding of CPPs to negatively charged cell 
surface proteoglycans, such as glycosaminoglycans, before they are internalized [262, 
263]. CPPs are then internalized by a variety of pathways, which can include direct 
translocation and various forms of endocytosis [49]
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While much has been learned about how CPPs function and their ability to deliver 
a wide range of therapeutic cargos has been demonstrated, CPPs have significant 
challenges to their use as delivery vectors. One of several important limitations to CPP-
mediated therapeutic delivery is poor cell and tissue specificity [260]. Because CPPs are 
capable of traversing the membrane of most cell types, delivery of the CPP and its cargo 
to targeted cells is reduced when non-target cells take them up. Additionally, nanoparticle 
and nanoscale conjugates that could potentially utilize CPPs as part of their delivery are 
also prone to untargeted delivery, due to uptake and removal by macrophage cells which 
rapidly remove most nanoscale delivery agents from circulation [65, 264]. Therefore, 
identifying factors that contribute to off-target uptake of CPP-nanoscale conjugates could 
potentially provide avenues to reduce the delivery of CPP-functionalized conjugates to 
non-targeted macrophage cells. 
 While the interaction between CPP-functionalized conjugates and cell surfaces 
has been subject to significant study, the interactions that CPPs have with proteins in the 
extracellular environment have received considerably less attention. Recently, Cedervall 
et al. discovered that the surface of nanoparticles become coated by a dynamic layer of 
proteins or “protein corona” [51]. This protein corona has been shown to be a significant 
player in the biological outcomes of nanoparticles, with distinct proteins in the corona 
being implicated in the toxicity, uptake, and other physiological responses to 
nanoparticles [54, 58, 265]. Nanoparticles functionalized with CPPs are also likely to 
form a protein corona which may impact cellular uptake. CPPs are known to interact with 
negatively charged proteins due to electrostatic interactions, but the consequences of 
these interactions on the delivery of the CPP cargo is not well known [266]. 
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Understanding how CPPs and CPP-functionalized nanoparticles interact with proteins in 
the biological medium is important to better utilize CPPs toward therapeutic delivery. 
While the composition of the nanoparticle protein corona impacts nanomaterial 
interactions with cells, the conformation of the proteins of the corona are also important 
in nanoparticle interactions with cells. Fleischer and Payne recently found that amine-
functionalized polystyrene nanoparticles denature the albumin present in their protein 
corona, and this denaturation leads to significant association of the particles to BS-C-1 
monkey kidney epithelial cells through scavenger receptors [60]. Likewise, Yan et al. 
found that  polymethacrylic acid nanoparticles denature albumin, which leads to uptake 
of the particles by differentiated THP-1 macrophage cells through the scavenger receptor 
[57]. These results demonstrate that charged polymeric nanoparticles denature albumin, 
which makes them susceptible to increased uptake by macrophages and potentially other 
cell types, but it is unclear if this may also extrapolate to other types of cationic nanoscale 
complexes. Because macrophages are known to preferentially uptake denatured proteins 
[267, 268], we predict that CPP-functionalized nanoparticles with a corona of denatured 
proteins are more likely to be taken up by macrophage than those that induce less protein 
denaturation. 
In this work, we aimed to understand if CPPs cause denaturation of serum 
albumin, and if this denaturation could contribute to uptake by macrophage cells. We first 
synthesized nanoscale complexes functionalized with a small library of model CPPs. 
Poly-l-lysine grafted with polyethylene glycol (PLL-g-PEG) and the protein glucose 
oxidase (GOX) were used to synthesize a model nanoscale complex to serve as a base for 
CPP functionalization. PLL-g-PEG/GOX complexes were then functionalized with the 
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CPPs Tat, Pen, and LMWP [45, 113, 269].  Once the CPP-PLL-g-PEG/GOX groups were 
synthesized, an albumin protein corona was formed around each complex. CPP 
functionalized complexes were found to produce alteration in albumin protein structure. 
Albumin denaturation was found to potentially significantly impact the uptake of CPP 
functionalized complexes by macrophage cells. 
4.2. Materials and Methods 
Fluorescein isothiocyanate (FITC), glucose oxidase (GOX), albumin, FITC-
albumin conjugate, Ellman Reagent, amiloride (cat.# A7410), chlorpromazine (cat.# 
C8138), genestein (cat.# G6649), and poly-l-lysine (15-30 kDa) (cat.# P7890) were 
purchased from Sigma Aldrich (St. Louis, MO). Cell penetrating peptides Tat 
(YGRKKRRQRRRC), Pen (RQIKIWFQNRRMKWKKC), and LMWP 
(CVSRRRRRRGGRRRR) were custom synthesized at greater than 95% purity by 
EZBiolab (Carmel, IN). Polyethylene glycol functionalized with succinimidyl ester 
(2kDa mPEG-NHS) and heterobifunctional polyethylene glycol with succinimidyl ester 
and maleimide (5 kDa Mal-PEG-NHS) were purchased from CreativePEGworks 
(Durham, NC). All other chemicals including DQ Green BSA (cat.#12050), those for 
polyacrylamide gel electrophoresis and cell culture, such as DMEM and fetal bovine 
serum (FBS), were purchased from Fisher Scientific (Pittsburgh, PA). RAW 264.7 mouse 
macrophage cells were purchased from ATCC (Manasses,VA). 
4.2.1 PLL-g-PEG Grafted Copolymer Synthesis 
 PLL-g-PEG was synthesized by methods previously used [9]. A 50/50 (w/w) 
mixture of 40 mg of 2 kDa mPEG-NHS and 5 kDa Mal-PEG-NHS was added to 15 mg 
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of 15-30 kDa PLL in phosphate buffered saline (PBS, pH 7.4) and allowed to react for 2 
hours. Unreacted PEG was then removed using a Pierce protein 10kDa concentrator. The 
grafted copolymer was then air-dried before storage at -20°C. H1-NMR was used to 
measure the extent of PEG grafting onto PLL, by dissolving an aliquot of the copolymer 
in D2O and using a Bruker Avance INOVA 400 MHz spectrometer. Peaks corresponding 
to the H of the α carbon of each lysine monomer at 4.2 ppm and H corresponding to the 
PEG conjugation to ϵ-amino groups at 2.55 ppm were integrated to determine the grafting 
ratio [270]. 
4.2.2 CPP-PLL-g-PEG/GOX Complex Formation 
 PLL-g-PEG/GOX complex formation was adapted from previous methods, using 
electrostatic interactions to drive association between PLL-g-PEG and GOX [9, 30, 36]. 
PLL-g-PEG (50 µl, 14 mg/ml, in PBS) was added to GOX (50 µl, 2 mg/ml, in PBS) 
while vortexing, and then allowed to incubate for one hour. After incubating, PLL-g-
PEG/GOX complexes were crosslinked using glutaraldehyde (0.003%) for 3 hours to 
stabilize the complexes. Following crosslinking, the complexes were functionalized with 
either Tat, Pen, or LMWP (Table 4.1) by adding 7×10-2 µmols of each of the peptides to 
the complexes and allowing thiol-reactive maleimide groups on PLL-g-PEG to react with 
the peptide cysteine thiol groups for 30 minutes. The extent of peptide conjugation was 
determined using Ellman’s reagent to measure the extent of unreacted peptide before and 
after conjugation [271]. The Ellman assay was performed following the manufacturers’ 
suggested protocol. The complexes were then washed using a 10 kDa centrifugal 
concentrator before use or storage at 4°C. 
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4.2.3 CPP-PLL-g-PEG/GOX Complex Characterization 
To confirm that each of the copolymers completely encapsulated GOX, a gel 
migration assay was used to measure association of the protein with the copolymer as 
previously described by our group [9]. Following synthesis, a 5 µl aliquot of each of the 
complexes was added to non-reducing SDS-PAGE sample buffer and loaded onto 8% 
SDS-PAGE gels. An equivalent loading of un-encapsulated GOX was used as a control 
for a non-encapsulated sample. The gel was then run at 200 V on a Bio-Rad Mini- 
PROTEAN Tetracell and stained using Coomassie G250 following completion. The 
intensity of the protein band corresponding to any non-encapsulated GOX was compared 
to the free GOX control to determine the extent GOX associated with each of the 
complexes. 
In order to characterize size and surface charge of the CPP-PLL-g-PEG/GOX 
complexes, the hydrodynamic diameter and ζ-potential were measured using dynamic 
light scattering (DLS) and phase analysis light scattering (PALS). A Brookhaven 
Instrument Corporation ZetaPALS ζ-potential analyzer was used for both measurements. 
Briefly, a 60 µl aliquot of CPP-PLL-g-PEG/GOX complexes were loaded into a cuvette 
that was placed into the instrument for DLS. Triplicate measurements consisting of at 
least five runs per measurement, with each run lasting one minute were used to determine 
the hydrodynamic diameter and polydispersity of the complexes. The surface charge of 
the CPP-PLL-g-PEG/GOX complexes were measured using PALS. CPP-PLL-g-
PEG/GOX complexes, synthesized as described above, were diluted to a volume of 1.5 
ml using PBS (pH 7.4) and loaded into a cuvette that was placed in the instrument. The ζ-
potential of the complexes was then calculated from their mobility using Smoluchowski’s 
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equation [243]. The measurements were made in triplicate, with each measurement 
consisting of 10 runs, each lasting one minute. 
4.2.4 Albumin Protein Corona Formation and Denaturation  
 
To determine if albumin forms a protein corona around CPP-PLL-g-PEG/GOX 
complexes, non-denaturing native PAGE was used to determine if albumin becomes 
bound to CPP-PLL-g-PEG/GOX complexes. Non-denaturing agarose gel electrophoresis 
has been similarly used to detect the formation of a protein corona around dendrimers and 
separate them from unbound protein [272]. CPP-PLL-g-PEG/GOX complexes were 
prepared as described above. A 5 µg aliquot of each CPP-PLL-g-PEG/GOX complex (by 
GOX concentration) was combined with bovine serum albumin (BSA) for a final albumin 
concentration of 5 µg/µl. The resulting BSA/CPP-PLL-g-PEG/GOX complexes were 
then allowed to incubate for 30 minutes at 37°C. A 1 µg aliquot of albumin- PLL-g-PEG-
CPP/GOX complexes (by GOX concentration) were then loaded onto 8% non-denaturing 
PAGE gels and run at 200V on a Bio-Rad Mini- PROTEAN Tetracell before staining 
with Coomassie G-250. The extent to which albumin binds to the complexes was 
compared to a control in which an equivalent amount of albumin was loaded onto the gel 
without complexes. Reductions in albumin migration compared to the control was used to 
evaluate albumin binding to the complexes. 
To determine the extent to which CPP-PLL-g-PEG/GOX complexes denature 
albumin that associates with the complexes as part of a protein corona, a fluorescence 
quenching assay with DQ Green BSA was used to detect changes in albumin structure. 
DQ Green BSA is an albumin which has been heavily labeled with BODIPY dye so that 
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its fluorescence has been self-quenched. Self-quenching fluorophores and other 
fluorescence based assays have been previously used to detect changes in protein 
structure [273]. CPP-PLL-g-PEG/GOX complexes were prepared as described above. An 
albumin protein corona was then formed, as described above, by incubating 5 µg aliquots 
of CPP-PLL-g-PEG/GOX complexes with DQ Green BSA at a final concentration of 5 
µg/µl. After either 30 or 60 minutes at 37°C, the fluorescence of the mixture was then 
measured (ex: 485 nm/ em: 535 nm) using a Beckman Coulter DTX 880 Multimode 
Detector. The extent of albumin denaturation was normalized (equation below) to DQ 
Green BSA that had not been incubated with complexes (negative control) and DQ Green 
BSA which had been boiled (positive control). 
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4.2.5 CPP-PLL-g-PEG/GOX and BSA/CPP-PLL-g-PEG/GOX Complex-
Macrophage Cell Association 
To determine the extent to which CPP-PLL-g-PEG/GOX and BSA/CPP-PLL-
PEG/GOX complexes associate with macrophage cells, fluorescence microscopy was 
used to visualize interaction of the complexes with macrophage cells. GOX was labeled 
with FITC, according to the manufacturer’s protocol, and was encapsulated in CPP-PLL-
g-PEG/GOX complexes. A mouse macrophage cell line, RAW 264.7 cells ,were first 
cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and maintained in 
an incubator maintained at 37°C and 5% CO2. Approximately 24 hours prior to 
visualizing the cells, 1×105 RAW 264.7 cells were seeded on polylysine-coated glass 
microscope coverslips. On the following day, CPP-PLL-g-PEG/GOX and BSA/CPP-
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PLL-g-PEG/GOX encapsulating FITC-GOX (10 µg by GOX concentration) were added 
to the cells in serum free DMEM. After 30 minutes of incubation at 37°C, the cells were 
washed with PBS and fixed with 4% formaldehyde. The coverslips were then mounted 
with ProLong Gold antifade mounting medium onto microscope slides before imaging 
with a Nikon Eclipse TE2000-U fluorescence microscope.  
4.2.6 Inhibition of Macrophage Uptake Pathways 
To better understand how albumin attachment to CPP-PLL-g-PEG/GOX 
complexes affects their uptake, pharmacological inhibitors were used to inhibit various 
forms of endocytosis (phagocytosis, macropinocytosis, caveolin dependent endocytosis, 
and clathrin mediated endocytosis) [274]. Prior to beginning the uptake studies, the 
cytotoxicity of each inhibitor was assessed using the Cell Titer Blue cell viability assay to 
ensure cell viability would be maintained above 90% [274, 275].  For uptake studies, 
RAW 264.7 cells were cultured, as described, before seeding on 96-well plates at 1×104 
cells/well. After one day, the medium of the cells was replaced with serum free DMEM. 
One hour before the experiment, amiloride (to inhibit phagocytosis and 
macropinocytosis), cholorpromazine (to inhibit clathrin mediated endocytosis), or 
genestein (to inhibit caveolae mediated endocytosis) were added to the cells for final 
concentrations of 4.5 µg/ml, 8 µg/ml, and 26 µg/ml, respectively. After one hour, 1 µg 
(by GOX mass) of FITC-labeled CPP-PLL-g-PEG/GOX or BSA/CPP-PLL-g-PEG/GOX 
were added to the cells. After 30 minutes at 37°C, Trypan Blue was added to the cells to 
quench any FITC fluorescence associated with non-internalized complexes [276, 277]. 
The fluorescence intensity was then measured (ex: 485 nm/em: 535 nm) using a 
Beckman Coulter DTX 880 Multimode Detector. 
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4.2.7 CPP-PLL-g-PEG/GOX Albumin Denaturation and Macrophage Uptake 
 To determine if RAW 264.7 cells take up denatured albumin differently than non-
denatured albumin, RAW 264.7 macrophage cells were cultured and seeded on 96-well 
plates at 1×104 cells/well as described above. FITC-albumin and boiled (denatured) 
FITC-albumin were added (5 µg) to RAW 264.7 cells in serum-free medium. Trypan 
Blue was then added to the cells to quench the fluorescence not associated with 
internalized protein, as described above. The fluorescence intensity was then measured at 
ex. 485 nm/em. 535 nm using a Beckman Coulter DTX 880 Multimode Detector. 
To understand the effect of albumin denaturation on uptake of CPP-PLL-g-
PEG/GOX complexes by macrophage cells, non-complex bound denatured albumin was 
used to partially saturate the uptake of the albumin bound complexes. CPP-PLL-g-
PEG/GOX complexes, with FITC GOX, were prepared as described above. The 
complexes were then incubated with either albumin or denatured albumin at 5 µg/µl at 
37°C for 30 minutes as also described above.  The albumin/CPP-PLL-g-PEG/GOX 
complexes (1 µg by GOX concentration) were then added to the RAW 264.7 cells in 
serum-free medium. The cells were allowed to incubate for 30 minutes at 37°C before 
Trypan Blue was added to quench FITC fluorescence of complexes in the medium or 
bound to the cell surface.  
This experiment was also similarly performed to detect the cytotoxic activity of 
GOX, using 5 µg of albumin/CPP-PLL-g-PEG/GOX, by rinsing the cells with PBS 
following a 30 minute incubation with the complexes, and assessing cell viability using 
the Cell Titer Blue cell viability assay following the manufacturer’s protocol. 
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4.2.8 Data Analysis 
 Each measurement was determined by taking the mean of the results of triplicate, 
biological replicate, samples. The error associated with the measurement was evaluated 
by determining the standard deviation from the mean. Statistical analysis were performed 
using the Student’s t-test, with a p-value of less than 0.05 to describe significant 
differences between two groups. 
4.3. Results 
4.3.1 CPP-PLL-g-PEG/GOX NP Formation and Characterization 
PLL-g-PEG-Mal was synthesized as previously described, resulting in 
approximately 10 PEG chains grafted onto each PLL backbone, as determined by H1 
NMR (Figure S1 in Appendix) [9]. Following synthesis of PLL-g-PEG-Mal, electrostatic 
interactions were used to complex PLL-g-PEG-Mal with GOX, as illustrated in line 1 of 
the synthesis scheme in Figure 4.1A. CPPs were conjugated through their cysteine thiol 
reacting with the PEG-maleimide. An Ellman assay indicated that approximately 7×10-2 
µmols of each CPP conjugated to the PLL-g-PEG/GOX complexes, representing 
conjugation of CPPs to nearly all available maleimide groups of the copolymer. Using 
SDS-PAGE, electrostatic association of the PLL-g-PEG copolymer to GOX and 
crosslinking of the complexes was confirmed through hindered migration of GOX 
through the gel (Figure 4.1B, Lane 4). Functionalization of PLL-g-PEG/GOX complexes 
with Pen, Tat, and LMWP CPPs showed similarly hindered migration of GOX during 




Table 4.1. Summary of CPPs Conjugated to PLL-g-PEG/GOX Complexes 
CPP CPP Sequence Est. CPP Net Charge R# 
Penetratin (Pen) RQIKIWFQNRRMKWKKC +7 3 
HIV Tat 47-57 (Tat) YGRKKRRQRRRC +9 6 
Low molecular weight protamine (LMWP) CVSRRRRRRGGRRRR +10 10 
 
 
Figure 4.1. Synthesis and Characterization of CPP-PLL-g-PEG/GOX Complexes. A: Synthesis 
schematic of CPP-PLL-g-PEG/GOX complexes; 1. PLL-g-PEG associates with GOX through electrostatic 
interaction. 2: PLL-g-PEG/GOX complexes were then functionalized with either the Pen, Tat, or LMWP 
CPPs. B: SDS-PAGE was used to determine the extent GOX remained associated with each of the 
complexes under denaturing conditions. Lane 1: Ladder; Lane 2: Empty; Lane 3: GOX; Lane 4: PLL-g-
PEG/GOX; Lane 5: Pen-PLL-g-PEG/GOX; Lane 6: Tat-PLL-g-PEG/GOX; Lane 7: LMWP-PLL-g-
PEG/GOX. C: Physicochemical characteristics (particle size, polydispersity index (PDI), and ζ-potential) 
were determined using DLS and PALS. 
 
Following synthesis, DLS and PALS were used to determine that the size and surface 
charge of the CPP-PLL-g-PEG/GOX complexes (Table 4.1C). PLL-g-PEG/GOX 
complexes were approximately 14 nm in diameter while functionalization with CPPs 
75 
 
resulted in complexes ranging in size from 14 -20 nm in diameter. PLL-g-PEG 
complexation with GOX resulted in complexes with a near neutral to slightly positive 
surface charge of 5 mV. The addition of CPPs increased the surface charge to 8.6, 9.5, 
and 10.5 mV for Pen, Tat, and LMWP functionalized complexes, respectively. 
4.3.2 Albumin Association to CPP-PLL-g-PEG/GOX Complexes 
To evaluate the extent to which albumin associates with CPP-PLL-g-PEG/GOX 
complexes, non-denaturing native PAGE was used to visualize changes in albumin 
migration down the gel (Figure 4.2A). Association of albumin to the complexes was 
determined by detecting changes in free albumin migration down the gel following 
incubation with the complexes compared to a control (lane 1) in which no complexes had 
been added. For all of the complexes, most of the albumin added to the samples remained 
unbound to the complexes, but slight changes in albumin migration were, nevertheless, 
observed. Upon the addition of PLL-g-PEG/GOX complexes to albumin (lane 2), a slight 
decrease in intensity of albumin that migrated down the gel was observed compared to 
the control. A similar decrease in albumin band intensity was also observed for Pen-PLL-
g-PEG/GOX complexes (lane 3). Much greater decreases in the intensity of the middle 
and lowest albumin bands were observed for Tat-PLL-g-PEG/GOX and LMWP-PLL-g-
PEG/GOX complexes (lanes 4 and 5), indicating that less albumin was able to freely 




Figure 4.2. Serum Albumin Forms a Protein Corona Around CPP-PLL-g-PEG/GOX Complexes. 
Panel A: Native PAGE of albumin/CPP-PLL-g-PEG/GOX complexes. Equivalent amounts of albumin 
were loaded with and without CPP-PLL-g-PEG/GOX complexes. Lane 1: Albumin (BSA); Lane 2: 
BSA/PLL-g-PEG/GOX; Lane 3: BSA/Pen-PLL-g-PEG/GOX; Lane 4: BSA/Tat-PLL-g-PEG/GOX; Lane 5: 
BSA/LMWP-PLL-g-PEG/GOX. Panel B: DQ Green BSA Fluorescence Quenching Assay. The 
fluorescence associated with DQ Green BSA following incubation with CPP-PLL-g-PEG/GOX complexes 
was evaluated after 30 and 60 minutes. DQ Green BSA (negative control) and boiled DQ Green BSA 
(positive control) were used as controls. * indicates p<0.05 when comparing differences between CPP-
PLL-g-PEG/GOX with PLL-g-PEG/GOX as determined by the Student’s t-Test. 
To monitor changes in albumin structure when in contact with CPP-PLL-g-
PEG/GOX complexes, a fluorescence quenching assay was used to observe perturbations 
in albumin structure (Figure 4.2B). Increases in fluorescence were associated with 
alteration in albumin structure. CPP-PLL-g-PEG/GOX complexes were incubated with 
non-denatured heavily labeled DQ Green BSA, and fluorescence measurements were 
taken after 30 and 60 minutes of incubation at 37°C. All results were normalized to DQ 
Green BSA alone (negative control) and boiled DQ Green BSA (positive control). PLL-
g-PEG/GOX and Pen-PLL-g-PEG/GOX complexes showed minor denaturation after 30 
minutes, which increased to approximately 25% of the positive control after 60 minutes. 
Tat-PLL-g-PEG/GOX complexes showed higher fluorescence associated with reduced 
fluorescence quenching compared to PLL-g-PEG/GOX and Pen-PLL-g-PEG/GOX 
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complexes. LMWP-PLL-g-PEG/GOX showed the greatest increase in fluorescence 
intensity, with the most fluorescence detected after both 30 and 60 minutes, compared to 
the other groups. After 60 minutes, the change in fluorescence of DQ Green BSA when 
incubated with Tat and LMWP functionalized PLL-g-PEG/GOX complexes was 
significantly different compared to that of the unmodified complexes. These results 
indicate that Tat and LMWP cause 25% of the denaturation of the positive albumin 
control after 60 minutes. 
4.3.3 Uptake of Albumin/CPP-PLL-g-PEG/GOX Complex by Macrophage Cells 
To determine if CPP-PLL-g-PEG/GOX and BSA/CPP-PLL-g-PEG/GOX 
complexes associate with macrophage cells, fluorescence microscopy was used to 
visualize the complexes following incubation with RAW 264.7 macrophage cells (Figure 
4.3).  CPP-PLL-g-PEG/GOX and albumin bound CPP-PLL-g-PEG/GOX (BSA/CPP-
PLL-g-PEG/GOX) complexes encapsulating FITC-labeled GOX became bound and/or 
internalized within macrophage cells after 30 minutes. LMWP-PLL-g-PEG/GOX 
complexes showed the greatest extent of association with macrophages, regardless of the 
presence of albumin. The other Pen and Tat modified complexes showed relatively 
similar extents of association with macrophages, which appeared to be slightly higher 
than that of the unmodified complexes. Complexes that had been incubated with albumin 
prior to addition to the cells generally resulted in similar association with macrophage 
cells as for unmodified complexes. LMWP-PLL-g-PEG/GOX complexes that had been 
pre-incubated with albumin tended to show slightly greater association with the 




Figure 4.3. CPP-PLL-g-PEG/GOX and Albumin/CPP-PLL-g-PEG/GOX Associate with Macrophage 
Cells. CPP-PLL-g-PEG/GOX and albumin/CPP-PLL-g-PEG/GOX complexes, encapsulating FITC labeled 
GOX, were allowed to incubate with RAW 264.7 mouse macrophage cells for 30 minutes. Fluorescence 
microscopy was used to observe association of the complexes with the cells. 
4.3.4 Albumin/CPP-PLL-g-PEG/GOX Complex Uptake Pathway by Macrophage 
Cells 
After determining that CPP-PLL-g-PEG/GOX complexes associate with 
macrophage cells, pharmacological inhibitors were used to evaluate the uptake 
mechanism of the complexes. By using Trypan Blue to quench the fluorescence of 
surface bound complexes, uptake of CPP-PLL-g-PEG/GOX and BSA/CPP-PLL-g-
PEG/GOX complexes was evaluated fluorometrically (Figure 4.4). PLL-g-PEG/GOX 
complexes showed a reduction in uptake in the presence of chlorpromazine and 
genestein, indicating that they are primarily taken up by clathrin and caveolae-mediated 
endocytosis (Figure 4.4A). When PLL-g-PEG complexes were associated with albumin, 
the uptake of the complexes were significantly reduced when caveolae-mediated 
endocytosis was inhibited by genestein. The other CPP-PLL-g-PEG/GOX complexes also 
showed a reduction in fluorescence when the cells had been incubated in the presence of 
chlorpromazine, suggesting uptake by clathrin-mediated endocytosis (Figure 4.4B-D). 
When the albumin bound CPP-PLL-g-PEG/GOX complexes were added to the 
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macrophages, however, significant reductions (p<0.05) in fluorescence were observed 
when the cells were treated with genestein compared to other pharmacological inhibitors. 
The reduced fluorescence for cells treated with genestein suggests that albumin 
complexed with CPP-PLL-g-PEG/GOX complexes were more favorably taken up by 
macrophages by a caveolae- mediated endocytosis uptake pathway.  
 
Figure 4.4. Macrophage Uptake Pathway of CPP-PLL-g-PEG/GOX and Albumin/CPP-PLL-g-
PEG/GOX Complexes. To evaluate how macrophages take up CPP-PLL-g-PEG/GOX and albumin/CPP-
PLL-g-PEG/GOX complexes, amiloride, chlorpromazine, and genestein were used to inhibit phagocytosis 
and macropinocytosis, clathrin-mediated endocytosis, and caveolae-mediated endocytosis, respectively. A: 
PLL-g-PEG/GOX and BSA/PLL-g-PEG/GOX; B: Pen-PLL-g-PEG/GOX and BSA/Pen-PLL-g-PEG/GOX; 
C: Tat-PLL-g-PEG/GOX and BSA/PLL-g-PEG/GOX; D: LMWP-PLL-g-PEG/GOX and BSA/LMWP-
PLL-g-PEG/GOX. * indicates that complexes with and without albumin, when treated with the same 






4.3.5 CPP-PLL-g-PEG/GOX Albumin Denaturation on Macrophage Uptake 
To determine if albumin denaturation within the protein corona of CPP-PLL-g-
PEG/GOX complexes influences the uptake of the complexes by macrophages, an excess 
of denatured albumin (5 mg/ml, in which most of the albumin would remain unbound to 
the complexes) and complexes were added to macrophage cells. If denatured albumin 
reduces the uptake of the complex, this would suggest that a receptor for denatured 
albumin participates in the uptake of CPP-PLL-g-PEG/GOX complexes. First, to verify 
that RAW 264.7 cells preferentially take up denatured albumin compared to albumin in 
its native state, the uptake of FITC-albumin was compared to FITC-albumin that had 
been boiled (Figure 4.5A). After 30 and 60 minutes, the uptake of denatured FITC-
albumin was approximately 10% and 80% higher compared to that of non-denatured 
FITC-albumin. 
Next, the impact of albumin on the internalization of CPP-PLL-g-PEG/GOX 
complexes by macrophage cells was determined (Figure 4.5B). All albumin-bound 
complexes were susceptible to uptake by macrophages, with the greatest fluorescence 
being detected for the Tat- and LMWP-functionalized complexes. When the complexes 
were pre-incubated with an excess of denatured albumin, however, the uptake of the 
complexes slightly decreased, but this was only statistically significant for LMWP-PLL-




Figure 4.5. Impact of Albumin Denaturation on Macrophage Uptake of CPP-PLL-g-PEG/GOX 
Complexes. A. Evaluation of RAW 264.7 uptake of FITC labeled albumin and denatured (boiled) FITC 
albumin after 30 and 60 minutes. Trypan Blue was used to quench extracellular fluorescence. B. Evaluation 
of RAW 264.7 uptake of CPP-PLL-g-PEG/GOX and albumin/CPP-PLL-g-PEG/GOX complexes, 
encapsulating FITC GOX, in the presence of cell culture concentrations of albumin or denatured albumin. 
Trypan Blue was used to quench extracellular fluorescence. C. Cell viability of RAW 264.7 cells after 30 
minute incubation with CPP-PLL-g-PEG/GOX in the presence of excess albumin and denatured albumin. 
The Cell Titer Blue cell viability assay was used to determine cell viability. * indicates a difference 
between two groups with p<0.05 as determined by the Student’s T-test. 
 
Additionally, as GOX is a cytotoxic protein, we expected that if the uptake of 
GOX could be blocked by saturating the uptake of the complexes with denatured 
albumin, the viability of the macrophage cells could be improved by adding an excess of 
denatured albumin to the cells with the complexes (Figure 4.5C). All CPP-PLL-g-
PEG/GOX complexes showed significant cytotoxicity to macrophage cells in the 
presence of albumin. The largest reduction of cell viability occurred for macrophages 
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treated with Tat- and LMWP-functionalized CPP-PLL-g-PEG/GOX complexes. When an 
excess of denatured albumin was added to the cells with the CPP-PLL-g-PEG/GOX 
complexes, the viability of the macrophage cells improved, with the most significant 
denatured albumin protection occurring for the Tat- and LMWP-functionalized 
complexes. This suggests that an excess of denatured albumin reduced the ability of the 
macrophage cells to take up the complexes, indicating that albumin denaturation plays a 
role in uptake.  
4.4. Discussion 
CPPs are emerging as promising carriers to facilitate the transport of 
biomacromolecules and nanoparticles into the cell interior [49]. Understanding what CPP 
characteristics tend to lead to off-targeted uptake will be important in the design of CPP- 
functionalized nanocarriers which avoid macrophage uptake. Macrophages are an 
important part of the immune system that remove damaged cells, cellular components, 
and harmful pathogens from the body [278]. Although they play this important role, they 
are also a barrier toward the application of novel nanomedicines in vivo due to their role 
in removal of nanomedicines from circulation [71]. In this work, we aimed to better 
understand how macrophages take up nanocarriers that are functionalized with CPPs, and 
the role that albumin may play in this uptake.  
In this work, we used GOX as part of a model CPP-functionalized delivery 
system to study the interaction of CPPs with albumin, and the effect of CPP interaction 
with albumin on macrophage uptake. When combined with PLL-g-PEG, GOX associated 
with the copolymer into nanoscale complexes, as determined by the decrease in GOX 
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mobility in PAGE as well as an increase in particle size to from approximately 9 nm to 
20 nm (Figure 4.1). This is a similar increase in particle size from that observed in earlier 
works by our group and others in which complexation of bovine serum albumin and 
buturylcholinesterase resulted in nanoscale complexes of about 20-30 nm in size [9, 36, 
37, 43]. Additionally, the particle size is similar to that of when Kawamura et al. used 
GOX to form nanoscale complexes with another cationic polymer, polyethylene glycol-
grafted-poly(allyl amine) for potential use in glucose sensors [279]. With the formation 
of PLL-g-PEG/GOX, the complexes were functionalized with several CPPs in order to 
understand how CPP characteristics affect the interaction of these complexes with 
albumin and what effect this interaction has on macrophage uptake.  
Albumin binds to CPP-PLL-g-PEG/GOX complexes which results in albumin 
denaturation. Incubation of CPP-PLL-g-PEG/GOX with BSA resulted in albumin binding 
to the complexes (Figure 4.2). Albumin in the protein corona of nanoparticles has been 
found to be subject to changes in conformation, with highly charged cationic or anionic 
particles leading to denaturation of the protein. This was observed by Fleischer and Payne 
for cationic polystyrene nanoparticles and by Yan et al. for anionic polymethacrylic acid 
nanoparticles [57, 60]. We similarly observed that CPPs also cause denaturation of 
albumin (Figure 4.2). The extent of albumin denaturation induced by CPPs tended to 
increase with arginine content of the CPPs, with Pen (three arginine residues) denaturing 
albumin the least and LMWP (ten arginine residues) denaturing albumin the most. The 
increase in albumin denaturation with increasing charge and arginine content is consistent 
with the work of others that observed albumin denaturation when bound to cationic 
nanoparticles [57, 60].  
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CPP-PLL-g-PEG/GOX and BSA/CPP-PLL-g-PEG/GOX complexes were taken 
up by macrophage cells (Figures 4.3 and 4.4). Uptake pathway studies showed that the 
CPP functionalized complexes tended to follow either a clathrin- or caveolae-mediated 
uptake pathways, depending on which CPP was used to functionalize the complexes. 
Non-endocytic uptake of the complexes were also possible. The addition of albumin, as 
part of the protein corona of the complexes, tended to shift this uptake pathway to more 
strongly favor caveolae-mediated endocytosis. Caveolae-mediated endocytosis is 
associated with the endocytosis of several types of receptor-ligand interactions [280]. 
This suggests the possibility that the uptake of the BSA/CPP-PLL-g-PEG/GOX 
complexes are internalized by macrophages using a receptor for denatured albumin. 
 Others have found that albumin denaturation as part of a nanoparticle protein 
corona was associated with uptake by scavenger receptors, through inhibition with poly-
inosinic acid [57, 60]. Although scavenger receptor uptake is often associated with 
phagocytosis, scavenger receptors have been shown to participate in other routes of 
endocytosis as well, including caveolae-mediated endocytosis [281, 282]. This suggest 
that scavenger receptors potentially play a role in the uptake of albumin bound CPP-PLL-
g-PEG/GOX complexes. 
Macrophage uptake of CPP-PLL-g-PEG/GOX complexes through albumin 
denaturation occurred if the CPP caused sufficient albumin denaturation. To determine 
the involvement of albumin denaturation of BSA/CPP-PLL-g-PEG/GOX complexes in 
their uptake by macrophages, excess denatured albumin was used to saturate receptors 
associated with the uptake of the denatured protein to inhibit uptake of the albumin bound 
complexes (Figure 4.5). Albumin denatured on its own was found to be taken up to a 
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greater extent than non-denatured albumin. This is in agreement with earlier studies that 
showed that phagocytic cells take up denatured albumin more than non-denatured 
albumin [267]. When an albumin protein corona was formed around CPP-PLL-g-
PEG/GOX complexes, a slight, non-statistically significant, increase in the uptake of 
most of the complexes was observed, but the overall uptake was largely comparable to 
that in albumin-free medium. The uptake of the complexes by macrophage cells tended to 
decrease, however, when an excess of denatured albumin was present along with the 
CPP-PLL-g-PEG/GOX complexes. This effect was only significant, however, for 
LMWP-functionalized complexes (p<0.05), which were also observed to cause the 
greatest extent of albumin denaturation of the CPPs compared to non-functionalized 
complexes (p<0.05). The ability to inhibit the uptake the complexes with denatured 
albumin suggest that albumin denaturation could contribute to the uptake of CPP-PLL-g-
PEG/GOX complexes by macrophage cells if sufficient denaturation occurs. 
The uptake of the complexes and the denaturation of albumin appears to be 
correlated to arginine content of the CPPs. Arginine content, within CPPs, is known to 
play an important role in the ability of the peptide to become internalized [283]. The 
number of arginine residues, and likely overall charge of the peptide, may also affect how 
the peptide interacts with multiple amino acids within albumin and cause changes in 
protein structure. Additional investigation is needed to more clearly separate the effect of 
charge and arginine content on protein denaturation. While this study only investigated 
the effect of CPP-functionalized complexes on albumin denaturation, it is likely that 
CPPs have the potential to denature other proteins that would form a protein corona 
around the complexes as well. Nanoparticles have been shown to induce denaturation of 
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other proteins, besides albumin, such as γ-globulin and insulin [74]. Additionally, 
complement proteins, such as C3, have been demonstrated to preferentially bind to 
denatured plasma proteins, resulting in their clearance from plasma [284]. This suggest 
that denaturation of albumin bound to CPP-PLL-g-PEG/GOX could potentially initiate 
the binding of complement type proteins, in addition to other proteins that may form a 
protein corona, and this denaturation could also contribute to clearance of the complexes 
by the immune system in an in vivo environment. Additional studies will be needed in 
subsequent work to better understand how CPP-induced albumin denaturation could 
contribute to the binding of other serum proteins to the complexes. Although the 
denaturation of albumin by CPP-PLL-g-PEG/GOX complexes was shown to alter how 
the complexes interact with immune cells in vitro, the effect of albumin denaturation on 
other aspects of the immune response and clearance of the complexes in vivo are also 
needed in future work. 
4.5. Conclusions 
 The CPPs Pen, Tat, and LMWP were used to functionalize PLL-g-PEG/GOX 
complexes, which were then used to better understand how CPPs interact with albumin. 
Each of the CPP-PLL-g-PEG/GOX complexes were found to denature albumin, with 
greater denaturation of albumin occurring with increasing charge and arginine content of 
the CPP. Albumin denaturation by CPPs resulted in uptake of CPP-PLL-g-PEG/GOX 
complexes by macrophages, primarily through caveolae-mediated endocytosis. Excess 
denatured albumin was found to inhibit uptake of the CPP-PLL-g-PEG/GOX complexes, 
suggesting receptor-mediated uptake of the complexes through the binding of denatured 
albumin, which is likely mediated through scavenger receptors. These results indicate 
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that CPPs with high charge or arginine content could be more likely to be taken up by 
macrophage cells. Although a wide variety of factors should contribute to selection and 
design of CPPs for the delivery of nanotherapeutics, the ability to avoid macrophage 
uptake and to have reduced impact on serum proteins should play an important role in the 







INTRACELLULAR DELIVERY OF GLUCOSE OXIDASE FOR ENHANCED 
CYTOTOXICITY TO PSMA EXPRESSING PROSTATE CANCER CELLS. 
 
5.1 Introduction 
Hydrogen peroxide and other reactive oxygen species (ROS), although naturally 
occurring as part of mammalian cell metabolic processes, are also potently cytotoxic 
[285]. ROS causes cytotoxicity through oxidative damage to biomolecules essential to 
normal cellular function, such as proteins, lipids, and DNA [78, 286-288]. Due to the 
cytotoxicity of ROS, the delivery of ROS or similar oxidative therapies has long been 
investigated in efforts to broaden and improve the strategies available to treat cancer [79-
81, 289, 290]. 
Although ROS has been of interest as an anticancer agent, the delivery of ROS to 
cancer cells and tumors is not trivial. Previous work has found that the delivery of ROS 
generators, rather than ROS itself, is the most practical approach to cause oxidative 
damage to cancer cells [80]. This approach was pioneered by Nathan & Cohn and Ben-
Yoseph & B.D. Ross in which microspheres containing glucose oxidase (GOX) and 
PEGylated GOX, respectively, were previously used as peroxide generators in order to 
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inhibit the growth of tumors in mice [79, 80]. GOX catalyzes the oxidation of β-D-
glucose, forming gluconic acid and hydrogen peroxide as products [291]. Ben-Yoseph & 
Ross found that PEGylated GOX was effectively cytotoxic to cancer cells in vivo, but due 
to the ubiquitous presence of glucose throughout the body, the use of antioxidant 
enzymes were also required to counter systemic toxicity [79].  
Recent work has emphasized the importance of localizing peroxide formation to 
the tumor tissue. To better control the delivery of peroxide formers, Fang et al. locally 
administered D-proline after i.v. injection of PEGylated D-amino acid oxidase, the 
substrate for another peroxide forming enzyme, where significant improvements in 
survival were demonstrated in mice bearing tumors of S-180 sarcoma cells [292]. Fan et 
al. used organosilica particles loaded with GOX and L-arginine to co-generate nitrous 
oxide and hydrogen peroxide to inhibit tumor growth [293]. Although GOX and other 
oxidases have been found to show strong potential to inhibit tumor growth when 
PEGylated or loaded into particles near cancer cells or within a tumor, it is unclear if the 
oxidase cytotoxicity could be further enhanced if the enzyme were taken up by cancer 
cells, rather than delivered locally to the cells. To determine if binding and intracellular 
delivery of GOX and other oxidases can potentially enhance their cytotoxicity, alternative 
strategies to deliver these cytotoxic proteins are needed. 
Cationic polymers, such as polylysine, polyethyleneimine, and polyamidoamine, 
have been used to modify and package numerous biomacromolecules, including nucleic 
acids and proteins [21, 294]. Charged copolymers and polyethylene glycol (PEG) have 
been found to be capable of electrostatic self-assembly with nucleic acids and proteins 
into nanoscale complexes [27, 295]. Complexation with PEGylated cationic copolymers 
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has been shown to improve aspects of delivery, including resistance to heat denaturation, 
protease degradation, stimuli-responsive delivery, as well as the ability functionalize 
proteins and DNA without covalent modifications, which are potentially deactivating [36, 
43, 296]. This approach has been successfully applied toward the encapsulation of 
proteins such as bovine serum albumin, butyrylcholinesterase, lysozyme, insulin, 
superoxide dismutase and others to modify how these proteins are delivered [9, 31, 36, 
297]. PEGylated cationic copolymers have been shown to permit proteins, as well as 
DNA, to cross the cell membrane, enabling delivered proteins to have activity within the 
intracellular space [29, 298].  
In this study, we aimed to enhance the cytotoxicity of GOX by delivering it 
intracellularly to prostate cancer cells expressing the prostate specific membrane antigen 
(PSMA). Prostate cancer cells express higher amounts of PSMA compared to healthy 
prostate cells [299-301]. PSMA is expressed at even higher levels when prostate cancer 
becomes androgen independent and the risk of metastasis increases [299]. Therefore, 
PSMA may be exploited to preferentially deliver a therapeutic, such as GOX or other 
drugs, to prostate cancer cells compared to healthy cells by using an anti-PSMA antibody 
[302]. We hypothesize that binding and internalization of oxidase enzymes directly to 
prostate cancer cells can potentially enhance the cytotoxicity of ROS-forming enzymes 
because the peroxides generated are likely cause more oxidative damage within the 
intracellular space. In this study, conditions were first identified that lead to effective 
association of GOX to the cationic copolymer poly-L-lysine-g-polyethylene glycol (PLL-
g-PEG), while retaining maximum enzyme activity. The PLL-g-PEG copolymer was then 
functionalized with monoclonal anti-PSMA monoclonal antibody to improve PLL-g-
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PEG/GOX binding and internalization into PSMA expressing cancer cells. The ability of 
anti-PSMA-PLL-g-PEG/GOX to generate ROS and cause cytotoxicity was then 
compared to unmodified GOX in vitro to determine if strategies to enhance binding and 
internalization of ROS- generating enzymes can be used to enhance their potency.  
5.2. Materials and Methods 
Glucose oxidase from Aspergillus Niger (cat.# G7141), poly-l-lysine (PLL) (15-30 
kDa) (cat.# P7890), dithiothreitol (DTT), 2’,7’ dichlorofluorescein diacetate (DCFHDA), 
fluorescein isothiocyanate (FITC) and the anti-PSMA monoclonal antibody clone 3A/12 
(cat.# MABC291) were purchased from Sigma Aldrich (St. Louis, MO). Polyethylene 
glycol (2 kDa mPEG-NHS and 5 kDa, maleimide-PEG-NHS) was purchased from 
Creative PEGworks (Winston Salem, NC). Pierce centrifugal concentrators (10 kDa and 
100 kDa), D-glucose, RPMI-1640 cell culture medium, Kaighn’s F-12K cell culture 
medium, fetal bovine serum, acrylamide and other chemicals needed for electrophoresis 
were purchased from Fisher Scientific (Hampton, NH). LNCaP and PC-3 cells were 
purchased from ATCC (Manasses, VA). Cell Titer Blue was purchased from Promega 
Corporation (Madison, WI). Phosphate buffered saline (PBS, pH 7.4) was made in-house. 
5.2.1 Copolymer Synthesis 
Poly-l-lysine-grafted-polyethylene glycol was synthesized using previously described 
methods [9]. Briefly, 15 mg of PLL was dissolved in 200 ul of PBS. Next, 40 mg of a 
50/50 (w/w) mixture of 2kDa mPEG-NHS and 5kDa maleimide-PEG-NHS was added to 
the dissolved PLL. The mixture was allowed to incubate for one hour before a 10 kDa 
Pierce centrifugal concentrator was used to wash unreacted polymer from the PLL-g-
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PEG-maleimide. The polymer was then dried and stored at -20°C until use. H1-NMR was 
used to determine the PEG grafting ratio onto the PLL backbone. An aliquot of polymer 
was dissolved in D2O and H1-NMR spectroscopy was performed on a Bruker INOVA 
400 NMR spectroscope. The PEG:PLL grafting ratio was then determined by integrating 
the peaks of the PEG linkage to PLL ε-amino groups at 2.55 ppm and the H-peak of PLL 
α- carbons at 4.2 ppm [270]. The ratio of the two integrated peaks was then used to 
calculate grafting ratio. 
5.2.2 Formation of Anti-PSMA-PLL-g-PEG/GOX 
PLL-g-PEG/GOX complexes were formed using previous methods to associate 
cationic copolymers with proteins [9]. Varying concentrations of PLL-g-PEG (25µl) were 
slowly added to GOX dissolved in PBS (2 mg/ml, 25 µl), while gently vortexing. The 
mixture was allowed to incubate for one hour at room temperature before the complexes 
were cross-linked to aid in their stability. To cross-link PLL-g-PEG/GOX, various 
concentrations of glutaraldehyde (5 µl) were added to the complexes and allowed to 
incubate for three hours at room temperature. PLL-g-PEG/GOX was then functionalized 
with partially reduced anti-PSMA monoclonal antibody as described below. 
Using methods described by Mahmoud et al., anti-PSMA monoclonal antibody was 
partially reduced using DTT to generate free thiol groups to enable conjugation of the 
antibody to PLL-g-PEG/GOX [303]. DTT was added to 50 µg of the anti-PSMA 
monoclonal antibody to a final concentration of 20 mM and allowed to incubate at 37°C 
for 30 minutes. For conjugation, the antibody was added to PLL-g-PEG/GOX complexes 
at a 1:1 mass ratio and allowed to incubate 30 minutes before washing with a 100 kDa 
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centrifugal concentrator. The complexes were then either used immediately or stored at 
4°C overnight before use. 
5.2.3 Association of PLL-g-PEG to GOX 
To determine if PLL-g-PEG associates with GOX, unmodified GOX and non-
crosslinked PLL-g-PEG/GOX (5 µg) were applied to non-denaturing 8% PAGE gels, and 
electrophoresis was performed on a Bio-Rad Mini-PROTEAN Tetracell gel 
electrophoresis system at 200V. After approximately 45 minutes, the non-denaturing gels 
were stained with Coomassie G-250 to visualize protein migration. 
SDS-PAGE (denaturing) was used to identify cross-linking conditions that would 
result in complexes resistant to protein release. Unmodified GOX and PLL-g-PEG/GOX 
cross-linked with varying concentrations of glutaraldehyde were applied to the gel (5 µg), 
and electrophoresis was performed on a Bio-Rad Mini-PROTEAN Tetracell gel 
electrophoresis system at 200V. After approximately 45 minutes, the SDS-PAGE gels 
were stained with Coomassie G-250 to visualize protein migration. SDS-PAGE was also 
used, following the same methods, to determine the size of antibody fragments (after the 
DTT reduction described above). 
5.2.4 PLL-g-PEG/GOX Enzymatic Activity  
The retention of GOX activity following PLL-g-PEG/GOX formation was evaluated 
with 2’,7’ dichlorofluorescein diacetate (DCFHDA) as a fluorescent indicator of the 
generation ROS, using methods from the work of LeBel et al. [304]. A stock solution of 
DCFHDA was first dissolved in ethanol (1 mM) before being further diluted in water (0.2 
mM) and allowed to incubate 30 minutes in the dark. DCFHDA solution (5 µM), FeSO4 
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(10 µM) and glucose (10 mM) were then combined in PBS as a substrate solution for the 
assay. The substrate mixture was then added to GOX or PLL-g-PEG/GOX complexes (50 
µg/ml normalized to GOX), and allowed to incubate 30 minutes in the dark. Fluorescence 
intensity (ex: 495 nm/ em: 535 nm) corresponding to ROS production was then measured 
using a Beckman Coulter DTX880 Multimode Detector. 
5.2.5 Anti-PSMA-PLL-g-PEG/GOX Physicochemical Characterization 
The physicochemical properties of PLL-g-PEG/GOX were determined using dynamic 
light scattering (DLS) to determine the complex size, and phase analysis light scattering 
(PALS) to determine the surface charge [9]. A Brookhaven Instrument Corporation 
ZetaPALS ζ-potential analyzer was used for both measurements. Briefly, a 60 µl aliquot 
of PLL-g-PEG/GOX was loaded into the instrument. Triplicate measurements consisting 
of at least five runs per measurement, with each run lasting 2 minutes, were used to 
determine the hydrodynamic diameter and polydispersity of the complexes. The surface 
charge of the complexes was measured using PALS. PLL-g-PEG/GOX complexes were 
diluted to a volume of 1.5 ml using PBS (pH 7.4). The ζ-potential was calculated from 
mobility using Smoluchowski’s equation [243]. Measurements were taken in triplicate, 
with each measurement consisting of 10 runs and each run lasting one minute. 
5.2.6 Prostate Specific Membrane Antigen (PSMA) Targeting 
Anti-PSMA-PLL-g-PEG/GOX cytotoxicity against PSMA expressing LNCaP 
cells and non-PSMA expressing PC-3 cells was used evaluate the effect of PSMA 
receptor targeting. LNCaP and PC-3 cells were cultured in RPMI 1640 and Kaighn’s F-
12K medium supplemented with 10% fetal bovine serum (FBS), respectively, at 37°C 
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and 5% CO2 before use. For experiments, LNCaP and PC-3 cells (1×104 cells/well) were 
cultured on 96-well plates one day before beginning the experiment. The LNCaP and PC-
3 cells (60% confluency) were then treated with GOX, PLL-g-PEG/GOX, or antiPSMA-
PLL-g-PEG/GOX at 10 µg/ml for 30 minutes in serum containing medium. The cells 
were then washed and their medium replaced before they were incubated another 24 
hours. The cell viability was determined using the Cell Titer Blue assay following the 
manufacturer’s suggested protocol. 
5.2.7 Anti-PSMA-PLL-g-PEG/GOX Cytotoxicity in Serum 
To determine how the presence of serum affects anti-PSMA-PLL-g-PEG/GOX 
cytotoxicity toward PSMA-expressing LNCaP cells, cell viability was assed using the 
Cell Titer Blue cell viability assay. LNCaP cells were grown to approximately 70% 
confluency in RPMI 1640 with 10% FBS in 5% CO2 before seeding on a 96-well plate at 
a density of 1×104 cells/well. After approximately 24 hours of incubation, the LNCaP 
cells were treated with PLL-g-PEG/GOX or anti-PSMA-PLL-g-PEG/GOX (5 µg/ml) in 
RPMI 1640 medium with either 0% or 10% FBS. The cells were exposed to the 
complexes for 30 minutes before they were removed, then the cells washed and the 
medium replaced with fresh RPMI 1640 medium with FBS. The cells were allowed to 
incubate for 2, 4, and 24 hours before Cell Titer Blue was used to assess cell viability 
following the manufacturer’s suggested protocol.  
5.2.8 Anti-PSMA-PLL-g-PEG/GOX Generation of ROS 
To determine if anti-PSMA-PLL-g-PEG/GOX cause oxidative damage to LNCaP 
cells, a DCFHDA assay was used to measure the intracellular generation of ROS. LNCaP 
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cells were grown to approximately 70% confluency in RPMI 1640 with 10% FBS in 5% 
CO2 before seeding on a 96-well plate at a density of 1×104 cells/well. After 24 hours, the 
cells were treated with 10 µM DCFHDA using methods described by Eruslanov et al. for 
detection of ROS [305]. DCFHDA was first dissolved in DMSO (10 mM) to produce a 
stock solution. Working concentrations of DCFHDA were produced by further dissolving 
DCFHDA stock solution in serum-free RPMI medium (10 µM). The LNCaP cell medium 
was then replaced with the RPMI medium with DCFHDA. After 30 minutes of 
incubation at 37°C, the DCFHDA was removed, the cells were washed, and fresh 
medium containing serum was added to the cells. Then the cells were treated with PLL-g-
PEG/GOX and antiPSMA-PLL-g-PEG/GOX for 30 minutes. The complexes were then 
removed, the cells washed, and the medium replaced with fresh medium. Trypan blue 
(0.1%) was added to the cells to quench extracellular fluorescence before measurements 
[276, 277]. The generation of ROS was detected fluorometrically over 24 hours using a 
Beckman Coulter DTX880 Multimode Detector (ex: 495 nm/em: 535 nm). 
5.2.9 Visualization of Anti-PSMA-PLL-g-PEG/GOX Uptake 
Fluorescence microscopy was used to visualize anti-PSMA-PLL-g-PEG/GOX 
uptake into LNCaP cells. Prior to complex synthesis, GOX was labeled with FITC using 
the manufacture’s recommended protocol. The FITC-labeled GOX was used make PLL-
g-PEG/GOX and anti-PSMA-PLL-g-PEG/GOX complexes as earlier described. LNCaP 
cells (2×105 cells) were seeded onto polylysine coated glass coverslips in 6-cm cell 
culture dishes. After incubating 24 hours, FITC-labeled GOX, PLL-g-PEG/GOX, and 
anti-PSMA-PLL-g-PEG/GOX (5 µg/ml) were then added to the cells in serum-free 
medium and allowed to incubate for 30 minutes at 37°C. Following 30 minutes of 
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exposure, the cell culture medium was removed and the cells washed with PBS to remove 
unbound complexes. The treated cells were then either fixed immediately or were 
allowed to incubate for 4 or 24 hours before fixation. The cells were treated with 4% 
formaldehyde for 15 minutes for fixation before a second wash with PBS. The glass 
coverslips were mounted using DAPI ProLong Gold antifade mounting medium (Life 
Technologies) on glass microscope slides. The cells were imaged with a Nikon Eclipse 
TE2000-U fluorescent microscope. 
5.2.10 Anti-PSMA-PLL-g-PEG/GOX Uptake Pathway 
To better understand how anti-PSMA-PLL-g-PEG/GOX is internalized by LNCaP 
cells, the mechanism of uptake of by the complexes was evaluated using pharmacological 
inhibitors with methods described by Keswani et al. [274]. LNCaP cells were grown to 
approximately 70% confluency in RPMI 1640 supplemented with 10% FBS before being 
seeded on 96-well plates at a density of 1×104 cells/well. Prior to uptake studies, the 
cytotoxicity of each inhibitor toward LNCaP cells was determined in order to treat the 
cells with the maximum amount of inhibitor without reducing cell viability below 90% 
[274]. The maximum concentration of inhibitor tolerable to the cells was then used for 
uptake studies. Approximately 24 hours after seeding LNCaP cells, the cell medium was 
replaced with serum-free RPMI 1640, two hours before addition of anti-PSMA-PLL-g-
PEG/GOX. To inhibit macropinocytosis, clathrin-dependent endocytosis, and caveolae-
dependent endocytosis, LNCaP cells were treated with amiloride (2.5 µg/ml), 
chlorpromazine (3 µg/ml), and genestein (1.7 µg/ml), respectively, one hour prior to the 
addition of the NP complexes [280]. Anti-PSMA-PLL-g-PEG/GOX (5 µg/ml) was then 
allowed to incubate with the cells for 30 minutes, then the cells were washed, and the 
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medium was replaced with fresh RPMI 1640 medium containing serum. The uptake of 
antiPSMA-PLL-g-PEG/GOX was determined through their cytotoxic activity toward the 
LNCaP cells, with the Cell Titer Blue assay being used to determine cell viability 24 




Figure 5.1 Anti-PSMA-PLL-g-PEG/GOX Synthesis Scheme. A. Electrostatic interaction was used to associate PLL-
g-PEG to GOX. PLL-g-PEG/GOX was then crosslinked with glutaraldehyde. B. PLL-g-PEG GOX was then 
functionalized with anti-PSMA monoclonal antibody through conjugation of the reduced antibody with cysteine groups 
with maleimide groups of the PLL-g-PEG. 
PLL-g-PEG-Mal was first synthesized in preparation for producing anti-PSMA-
PLL-g-PEG/GOX. H1 NMR spectroscopy (Appendix, S1) confirmed PEG conjugation 
onto PLL, with a grafting ratio of approximately 10 PEG chains to each PLL chain. PLL-
g-PEG was then able to be complexed with GOX as described in Figure 5.1A through 
electrostatic attraction between PLL ϵ-amino groups and negatively charged residues on 
GOX. To determine an effective range at which PLL-g-PEG associates with GOX, PLL-
g-PEG was added to the enzyme at different copolymer to protein (C:P) ratios. Native 
PAGE (non-denaturing) was then used to evaluate association of the polymer with the 
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protein through the lack of protein migration into the gel. In Figure 5.2A, the protein 
corresponding to GOX disappeared upon addition of PLL-g-PEG at a 1:1 C:P ratio. GOX 
was also unable to migrate through the gel at higher C:P, indicating that PLL-g-PEG 
associates with GOX at C:P ratios from 0.37:1-7:1. We proceeded with a C:P ratio of 7:1 
to reduce the number of potential samples for later studies. 
 
Figure 5.2. Characterization of AntiPSMA-PLL-g-PEG GOX. A. Native PAGE of GOX combined with PLL-g-
PEG. Lane 1: Free GOX; Lane 2: 0.37:1 C:P PLL-g-PEG/GOX; Lane 3: 0.75:1 C:P PLL-g-PEG/GOX; Lane 4: 1.5:1 
C:P PLL-g-PEG/GOX; Lane 5: 3:1 C:P PLL-g-PEG/GOX; Lane 6: 7:1 C:P PLL-g-PEG/GOX. B. SDS- PAGE of GOX 
combined with PLL-g-PEG. Lane 1: Ladder; Lane 2: Empty; Lane 3: Free GOX; Lane 4: 7:1 C:P PLL-g-PEG/GOX 
with 0% glutaraldehyde; Lane 5: 7:1 C:P PLL-g-PEG/GOX with 0.06% glutaraldehyde; Lane 6: 7:1 C:P PLL-g-
PEG/GOX with 0.12% glutaraldehyde. C. AntiPSMA antibody sulfydryl reduction using DTT after 37°C for 30 
minutes. Lane 1: Ladder; Lane 2: AntiPSMA antibody; Lane 3: Reduced antiPSMA antibody. D. Physicochemical 




After identifying conditions at which PLL-g-PEG would associated to GOX, 
PLL-g-PEG/GOX was cross-linked with glutaraldehyde to make them resistant to protein 
release under physiological conditions. SDS-PAGE was used to determine the cross-
linking conditions at which PLL-g-PEG would remain associated with glucose oxidase 
(GOX) under denaturing conditions (Figure 5.2B). Under denaturing conditions, non-
crosslinked GOX was unable to remain fully associated with PLL-g-PEG as a protein 
band of similar density migrated the same distance as unmodified GOX (lane 4). Upon 
addition of 0.06% glutaraldehyde, GOX was able to remain fully associated the PLL-g-
PEG (lane 5). 
5.3.2 Anti-PSMA-PLL-g-PEG/GOX Characterization 
Once conditions were identified that would lead to effective encapsulation of 
GOX to form PLL-g-PEG/GOX, the complexes were functionalized with the anti-PSMA 
antibody to enhance the binding and uptake of the complex by LNCaP cells. Anti-PSMA 
was partially reduced to expose free sulfhydryl groups within the antibody. DTT 
reduction resulted in antibody fragments of approximately 130 kDa, 100 kDa, and 20 
kDa (Figure 5.2C). FITC labeling of the antibody indicated that typically one antibody 
was conjugated per eight GOX enzymes prepared as PLL-g-PEG/GOX (not shown). 
DLS and PALS were used to determine particle size and ζ- potential of anti-
PSMA-PLL-g-PEG/GOX (Table 5.2D). Using DLS, the size of the enzyme was found to 
be 9 nm, PLL-g-PEG/GOX was 15 nm, and anti-PSMA-PLL-g-PEG/GOX was 30 nm. 
The ζ- potential of PLL-g-PEG/GOX and anti-PSMA-PLL-g-PEG/GOX were found to 
be near neutral with a slightly positive charge. 
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5.3.3 Retention of GOX Activity Following PLL-g-PEG/GOX Association 
 
Figure 5.3. Effect of Glutaraldehyde Treatment on PLL-g-PEG/GOX Activity. The complexes were incubated 
with 10mM glucose as a substrate. * indicates that GOX and PLL-g-PEG/GOX with 0% glutaraldehyde had a p<0.05 
when a Student’s t-Test was used to compare differences between the groups. ** indicates that PLL-g-PEG/GOX with 
0% glutaraldehyde and PLL-g-PEG/GOX with other concentrations of glutaraldehyde had a p<0.05 when a Student’s t-
Test was used to compare differences between the two groups. 
To determine how PLL-g-PEG association with GOX affected the activity of the 
enzyme, the generation of H2O2 was detected using a DCFHDA assay (Figure 5.3). 
Association of the GOX with PLL-g-PEG was not found to negatively impact enzyme 
activity, as no observable reduction in fluorescence occurred. The addition of 0.06% 
glutaraldehyde, however, was found to reduce enzyme activity to 80% relative to the 
unmodified enzyme. Further increasing the amount of glutaraldehyde was found to 
further reduce enzymatic activity. Because effective association of the enzyme was 
retained under denaturing conditions with 0.06% glutaraldehyde, this concentration was 
used for all subsequent synthesis of GOX complexes. 
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5.3.4 Cytotoxicity of Anti-PSMA-PLL-g-PEG/GOX 
 To determine if functionalization of PLL-g-PEG with anti-PSMA alters GOX 
cytotoxicity toward cancerous cells, the cell viability of PSMA-expressing LNCaP and 
non-PSMA-expressing PC-3 prostate cancer cells was evaluated after treatment with 
GOX, PLL-g-PEG/GOX, and anti-PSMA-PLL-g-PEG/GOX (Figure 5.4). GOX alone did 
not show any significant cytotoxicity when incubated with both cells lines at a 
concentration of between 0.1-10 ug/ml. When GOX was combined with PLL-g-PEG, 
PLL-g-PEG/GOX either had no effect or only slightly reduced the viability of both cell 
types. When PLL-g-PEG/GOX was functionalized with anti-PSMA antibody, the 
viability of LNCaP cells was significantly reduced to ~35% viability (p<0.05) after a 30 
minute exposure to the anti-PSMA-PLL-g-PEG/GOX complexes at 10 µg/ml. In contrast, 
PC-3 cells only had a 20% reduction in cell viability relative to the untreated cells under 
the same conditions. 
 
Figure 5.4. Cell viability of LNCaP (PSMA +) and PC-3 cells (PSMA -) after a 30 minute treatment with GOX, 
PLL-g-PEG/GOX, and Anti-PSMA-PLL-g-PEG/GOX. Each cell type was treated with either 10, 1, or 0.1 µg/ml 
(by GOX concentration) of each sample type. After 30 minutes, the medium over the cells was removed, washed and 
replaced with fresh medium. The cell viability was normalized to cells that were untreated (negative control) and cells 
treated with isopropanol (positive control). * indicates that differences between LNCaP and PC-3 cells had a p<0.05 





5.3.5 Anti-PSMA Reactive Oxygen Species Formation and Cytotoxicity 
 
Figure 5.5. Anti-PMA-PLL-g-PEG/GOX Cytotoxicity and Generation of Reactive Oxygen Species. A. The 
cytotoxicity of PLL-g-PEG/GOX and anti-PSMA-PLL-g-PEG/GOX (5 µg by GOX concentration) toward LNCaP cells 
was evaluated over 24 hours in the presence and absence of serum, using the Cell Titer Blue cell viability assay. B. The 
generation of intracellular ROS within LNCaP cells after incubation with PLL-g-PEG/GOX and anti-PSMA-PLL-g-
PEG/GOX (1µg by GOX concentration) was evaluated by the DCFDA assay over 24 hours. * indicates a difference 
with a p<0.05 between untreated LNCaP cells and cells treated with anti-PSMA-PLL-g-PEG/GOX, determined by the 
Student’s t-Test. C. The generation of intracellular ROS in LNCaP cells over 24 hours by anti-PSMA-PLL-g-
PEG/GOX at GOX concentrations of 1 µg/ml, and 2.5 µg/ml. 
 
To determine if serum impacts the ability of anti-PSMA-PLL-g-PEG/GOX to 
induce cytotoxicity in LNCaP cells, the viability of the cells was evaluated in the 
presence and absence of serum (Figure 5.5A). When LNCaP cells were treated with the 
complexes in serum-free medium, the viability of LNCaP cells was reduced to 
approximately 60% after 2 hours. The viability further reduced to approximately 40% 
after 24 hours compared to untreated cells.  The cytotoxicity of both PLL-g-PEG/GOX 
and anti-PSMA-PLL-g-PEG/GOX were similar to one another in serum-free conditions, 
with the anti-PSMA complexes being only slightly more cytotoxic (Figure 5.5A). When 
LNCaP cells were treated with PLL-g-PEG/GOX and anti-PSMA-PLL-g-PEG/GOX in 
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serum-containing medium, the cytotoxicity of both types of complexes was significantly 
reduced relative to serum-free conditions. PLL-g-PEG/GOX had only negligible 
cytotoxicity (90-100% cell viability), while anti-PSMA-PLL-g-PEG/GOX significantly 
reduced (p<0.05) cell viability compared to control cells. This suggest that, although 
serum prevents some of the interactions of PLL-g-PEG/GOX that induces LNCaP 
cytotoxicity, the anti-PSMA antibody was able to prevent a complete loss of activity of 
the complexes toward the LNCaP cells. 
To determine if ROS are formed within the time-course that anti-PSMA-PLL-g-
PEG/GOX causes cytotoxicity, a DCFDA assay was used to detect changes in ROS 
formation in LNCaP cells. Upon incubation with anti-PSMA-PLL-g-PEG/GOX, an 
increase in fluorescence associated with ROS formation was detected almost immediately 
after incubation compared to untreated cells (Figure 5.5B). Additionally, elevated ROS 
levels were detected over a similar time-course as cytotoxic effects were observed 
(Figure 5.5C). These results suggest that anti-PSMA-PLL-g-PEG generated intracellular 
ROS in conjunction with losses in cell viability. 
5.3.6 Visualization of Binding and Uptake of Anti-PSMA-PLL-g-PEG/GOX 
The binding and uptake of anti-PSMA-PLL-g-PEG/GOX was observed using 
fluorescence microscopy. In Figure 5.6A, the fluorescence of PLL-g-PEG/GOX, anti-
PSMA-PLL-g-PEG/GOX were compared to unmodified GOX after four hours. LNCaP 
cells treated with PLL-g-PEG/GOX and anti-PSMA-PLL-g-PEG/GOX had much more 
FITC fluorescence compared to unmodified GOX. Anti-PSMA-PLL-g-PEG/GOX 
showed comparable FITC fluorescence to PLL-g-PEG/GOX, but the fluorescence was 
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slightly more distributed among the cells. These results demonstrate that anti-PSMA-
PLL-g-PEG/GOX and PLL-g-PEG/GOX associate with LNCaP cells. 
 
 
Figure 5.6. Visualization of Anti-PSMA-PLL-g-PEG/GOX Association with LNCaP Cells. Fluorescence 
microscopy was used to observe anti-PSMA-PLL-g-PEG/GOX association with LNCaP cells. LNCaP cell nuclei were 
statined with DAPI (top rows). GOX and GOX encapsulated within PLL-g-PEG/GOX and anti-PSMA-PLL-g-
PEG/GOX were stained with FITC (middle rows). The third rows are an overlay of DAPI and FITC for each group. A. 
A comparison of association between GOX, PLL-g-PEG/GOX, and anti-PSMA-PLL-g-PEG/GOX with LNCaP cells 











In Figure 5.6B, anti-PSMA-PLL-g-PEG/GOX was incubated with LNCaP cells, 
and the cells were fixed at different time points after addition of the complexes. At 30 
minutes, cell nuclei were small and distinct while FITC fluorescence showed signs of 
being both diffuse and punctate within the cells, suggesting that the complexes localize 
within endosomes. After four hours, cell nuclei were still distinct and FITC fluorescence 
was more diffuse in the cell than after 30 minutes, indicating that the complexes were 
likely released into the cytosol. Additionally, much of the FITC fluorescence was found 
near cell nuclei as opposed to the 30 minute time point. After 24 hours, DAPI staining of 
the nuclei showed more indistinct nuclei with almost all of the FITC fluorescence co-
localized as opposed to what was seen at earlier time points. These images suggests that 
internalized anti-PSMA-PLL-g-PEG/GOX eventually co-localize with the nucleus once 
internalized in LNCaP cells. 
5.3.7 Mechanism of Anti-PSMA-PLL-g-PEG/GOX Cellular Uptake 
 The mechanism of anti-PSMA-PLL-g-PEG/GOX uptake was assessed using 
pharmacological inhibitors, followed by evaluating the cytotoxic activity of the 
complexes (Figure 5.7). LNCaP cells had significantly improved viability when 
incubated with chlorpromazine (10%) (p<0.05) and genestein (20%) (p<0.01), but not 
with amiloride. The improved viability after incubation with chlorpromazine and 
genestein suggests that caveolae-mediated endocytosis plays an important role in the 
uptake of anti-PSMA-PLL-g-PEG/GOX, with clathrin-mediated endocytosis also having 




Figure 5.7. Effect of endocytosis inhibitors on Anti-PSMA-PLL-g-PEG/GOX cytotoxicity to LNCaP cells. 
LNCaP cells were treated with amiloride, chlorpromazine, and genestein to inhibit macropinocytosis, clathrin mediated 
endocytosis, and caveolae mediated endocytosis prior to addition of anti-PSMA-PLL-g-PEG/GOX. * indicates p<0.05 
and ** indicates p<0.01 when the Student’s t-Test was used to compare differences between the untreated group and 
treated groups. 
5.4. Discussion 
Prostate cancer is a significant health burden on society, affecting 11.6% of all 
men at some point in their lifetime [306]. Glucose is important for tumors to remain 
viable and grow, which was first identified by Warburg over 90 years ago [307]. Several 
types of cancer, including prostate cancer, have been found to be susceptible to metabolic 
stress, with glucose depletion resulting in the formation of excessive cytotoxic 
mitochondrial ROS [308]. A novel approach toward cancer treatment is to deliver 
cytotoxic hydrogen peroxide to the cancer while simultaneously reducing the amount of 
glucose available for cancer cell metabolism [81]. High levels of hydrogen peroxide and 
others forms of ROS can result in nuclear and mitochondrial DNA damage, protein 
carbonylation, and lipid peroxidation, which in turn results in multiple cell signaling 
pathways that lead to apoptosis [309]. This suggests that prostate cancer and other types 
108 
 
of cancer can be treated if subjected to glucose depletion in conjunction with generation 
of high levels of ROS. 
The feasibility of this approach was first demonstrated by Nathan & Cohn, by i.p. 
injection of GOX conjugated to latex microspheres; they delivered a peroxide generator 
that was able to prolong the survival of mice treated with P388 lymphoma cells [80].  
Ben-Yoseph & B.D. Ross similarly found that intratumorally administered PEGylated 
GOX could be used to inhibit the growth of solid tumors in mice formed from 9L glioma 
cells [79]. Although PEGylated GOX was demonstrated to reduce tumor volume in 
conjunction with a reduction in intratumoral ATP, a lack of retention of the enzyme in the 
tumor tissue required that SOD and catalase anti-oxidant enzymes be administered to the 
mice to prevent systemic toxicity. These early studies show that, although GOX is 
effective at inhibiting the growth of multiple types of cancer cells and tumors, ensuring 
that GOX is locally delivered is critical for the enzyme to be effective and not to cause 
toxicity to other tissues. 
The potential of GOX to deprive tumors of glucose while generating hydrogen 
peroxide has recently received renewed interest. Zhao et al. developed poly (FBMA-co-
OEGMA) nanogels entrapping GOX to form 800 nm particles as a novel treatment for 
melanoma [310]. After intratumoral injection in mice, the authors observed significant 
antitumor activity from the GOX nanogels with no observable damage to the kidney, 
liver, or heart of the mice. In another recent example, Fan et al. conjugated GOX to the 
surface of arginine-loaded hollow mesoporous silica nanoparticles to form 180 nm 
particles, which co-generated NO and H2O2. [293]. Tumor-bearing mice that received 
treatment with the GOX nanoparticles survived significantly longer than untreated mice 
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or mice that received nanoparticles without the surface bound GOX. These recent studies 
likewise demonstrate that disruption of glucose metabolism in parallel with peroxide 
formation is an effective treatment for several types of tumors and causes little toxicity if 
delivered near the tumor. 
Although GOX and other peroxide generators have shown significant promise in 
prolonging the survival of mice with several types of tumors, controlling the delivery of 
GOX so that it has proximity to tumor tissue is important for it to be safe while 
effectively cytotoxic. In this study, we aimed to demonstrate that GOX could be made to 
be more cytotoxic toward PSMA-expressing prostate cancer cells if they were delivered 
in a way that enhanced the cell binding and internalization of the enzyme. If the enzyme 
can be delivered directly into cancer cells, smaller quantities of enzyme would be needed 
to induce cancer cell cytotoxicity, making the delivery of GOX more safe and effective. 
Our approach aimed to further improve the delivery of GOX by selectively 
delivering the enzyme intracellularly by forming using PLL-g-PEG and an anti-PSMA 
monoclonal antibody to form anti-PSMA-PLL-g-PEG/GOX complexes. GOX readily 
associated with PLL-g-PEG into nanoscale complexes (Figure 5.2). GOX retained 
enzymatic activity toward glucose, which was evident by the release of H2O2 while 
associated with the copolymer (Figure 5.3). This is consistent with others who have 
found that small molecule substrates are accessible to enzymes within similar complexes 
without severely compromising activity [37, 311].  
We further functionalized the GOX complexes by producing antibody fragments 
from a monoclonal antibody, which had previously been developed and shown to bind 
effectively to PSMA-expressing prostate cancer cells and used for the delivery of 
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imaging agents and nanoparticles [302, 312]. Improvements in the cell binding of DNA 
polyplexes through the use of antibodies have been observed by others and were expected 
to produce the same benefit to PLL-g-PEG/GOX [313]. 
Anti-PSMA-PLL-g-PEG/GOX was found to be significantly more cytotoxic 
toward LNCaP cells than unmodified GOX at equivalent concentrations of the enzyme 
(Figure 5.4). PLL-g-PEG/GOX also demonstrated significant cytotoxicity, but this effect 
was negated by the presence of serum proteins (Figure 5.5A). Serum and other proteins 
are known to bind to the surfaces of nanoparticles as a “protein corona” which likely 
reduces the ability of PLL-g-PEG/GOX to interact as effectively with the cells [51].  
Functionalizing PLL-g-PEG/GOX with the anti-PSMA antibody was found to restore 
part of the cytotoxicity of GOX complexes in the presence of serum (Figure 5.5A). This 
suggest that the delivery of PLL-g-PEG/GOX can be controlled to cell types of interest 
through the use of ligands, such as antibodies.  
To determine if the greater cytotoxicity can be attributed to better binding and/or 
internalization of GOX when modified as anti-PSMA-PLL-g-PEG/GOX, fluorescence 
microscopy was used to visualize GOX interaction with LNCaP cells (Figure 5.6). 
Fluorescence associated with anti-PSMA-PLL-g-PEG/GOX and PLL-g-PEG/GOX was 
observed to be much greater than that of unmodified GOX in serum-free conditions, 
indicating that PLL-g-PEG and anti-PSMA improve localization of the protein to the 
cells. In the presence of serum, however, anti-PSMA functionalization maintained uptake 
of the PLL-g-PEG/GOX complexes, while uptake of non-functionalized complexes was 
reduced (Figure 5.5A). Over the course of 24 hours, anti-PSMA-PLL-g-PEG/GOX 
showed increased co-localization with LNCaP nuclei, which is consistent with the 
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behavior of PLL-g-PEG when complexed with DNA as a gene delivery vector [314]. Co-
localization of anti-PSMA-PLL-g-PEG/GOX with the nuclei suggest the superior 
cytotoxicity could potentially be due to increased peroxide generation near nuclear DNA, 
resulting in more oxidative DNA damage and increased cytotoxicity.  
Anti-PSMA-PLL-g-PEG/GOX internalization by LNCaP cells is primarily 
mediated by clathrin- and caveolae-mediated endocytosis (Figure 5.7). Uptake by a 
caveolae endocytosis pathway may be beneficial for the complexes to induce 
cytotoxicity, as endosomes formed along these pathways are not expected to further 
develop into lysosomes, which may better protect the enzyme from proteolytic 
degradation.  
ROS generation is consistent with GOX conversion of glucose into H2O2 and 
gluconic acid [291]. The intracellular generation of ROS was higher for anti-PSMA-PLL-
g-PEG/GOX compared to untreated control cells (Figure 5.5C). PLL-g-PEG/GOX 
showed higher ROS generation than untreated control cells as well, but the increase was 
not significant (Figure 5.5B). The elevated generation of ROS and subsequent 
cytotoxicity for LNCaP cells treated with anti-PSMA-PLL-g-PEG/GOX, suggests that 
GOX is more cytotoxic to LNCaP cells when delivered into the cell interior.  
5.5 Conclusions 
 Cytotoxic proteins have the potential provide additional means to treat cancer, but 
aspects of their delivery have limited their use. One of the biggest challenges to the use of 
peroxide-forming cytotoxic proteins, as with other chemotherapy drugs, is controlling 
delivery so as to deliver sufficient amounts of the enzyme to be toxic but cause minimal 
oxidative stress toward untargeted cells. In this proof-of-concept study, we sought to 
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improve one aspect of peroxide-forming protein delivery by delivering them into the 
intracellular space.  
We found that GOX cytotoxicity could be enhanced to PSMA-expressing prostate 
cancer cells by modifying the enzyme with the cationic copolymer PLL-g-PEG and an 
anti-PSMA antibody. These modifications enabled enhanced binding and uptake of the 
enzyme in PSMA-expressing LNCaP cells compared to similar cells that lacked the 
PSMA receptor. Ultimately, concentrations of unmodified GOX that were non-toxic to 
LNCaP cells were cytotoxic once administered as an anti-PSMA-PLL-g-PEG/GOX 
complex. These results demonstrate that a practical means to enhance the cytotoxicity of 
GOX and potentially other peroxide forming proteins is to deliver them intracellularly. 
The modular design of the complexes also makes it possible for antibodies targeting other 
cancer cell markers to be utilized to facilitate intracellular delivery of a protein. Further 
optimization of anti-PSMA-PLL-g-PEG/GOX and assessing the performance of the 
complexes in vivo are planned in our future work to better develop GOX and other 









Proteins are large biomolecules that are capable of performing a wide range of 
biochemical reactions. The ability of proteins to accomplish a diverse range of 
biochemical tasks needed for cell survival makes many of them a member of an 
important group of potential therapeutics. In order for proteins to be effective 
therapeutics, however, they must be able to reach the location they are needed while also 
avoiding uptake by the immune system.  
In this work, the copolymer PLL-g-PEG and other materials were used to alter the 
characteristics of proteins in order to improve aspects of their delivery. Using albumin as 
a model protein, structural characteristics of PLL-g-PEG were found to not only alter the 
ability of the copolymer to associate with the protein but to also impact the stability of 
PLL-g-PEG NP complexes. A 7:1 copolymer to protein ratio worked best for completely 
associating the protein with the copolymer and for producing stable NP complexes. 
Moreover, proteins encapsulated in PLL-g-PEG NP complexes were found to retain   
114 
 
their activity toward small molecule substrates. 
 The PLL-g-PEG NP complexes were then functionalized with CPPs. CPPs are 
short, typically cationic peptides, that are capable of transporting a wide variety of cargos 
across the cell membrane. As CPPs are highly cationic and likely to interact with serum 
proteins on their route to deliver PLL-g-PEG NP complexes, we studied the effect that 
CPPs have on albumin and macrophage uptake. CPPs, as part of PLL-g-PEG NP 
complexes, denature albumin with increasing charge and arginine content. Albumin was 
shown to participate in the uptake of CPP PLL-g-PEG NPs by macrophages, likely 
through a scavenger receptor. 
The use of targeting ligands can improve the selectivity at which PLL-g-PEG NP 
complexes are delivered to particular cell types. This was demonstrated by 
functionalizing PLL-g-PEG NP complexes with an anti-PSMA monoclonal antibody to 
deliver the cytotoxic protein, GOX, to PSMA-expressing cancer cells. GOX was found to 
produce ROS within PSMA-expressing LNCaP cells, leading to the cytotoxicity of the 
PLL-g-PEG NP complexes. This work suggests that intracellular delivery of ROS- 
producing enzymes make the enzyme more cytotoxic to LNCaP cancer cells and 
potentially other types of targeted cancer cells as well. 
While this work demonstrates that protein encapsulation within PLL-g-PEG NPs 
can be used to modify how proteins interact with cells and other proteins in the biological 
environment, additional future work is needed to make PLL-g-PEG NPs better protein 
delivery vectors. A few key topics of future potential research to improve PLL-g-PEG NP 
complexes are listed below: 
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• PLL-g-PEG NP complexes are unable to release the protein they 
encapsulate. While this is a strength for encapsulating proteins that 
interact with small molecule substrates, this may hinder other proteins that 
interact with larger biomacromolecules. Identifying ways to release the 
encapsulated protein, in a controlled manner, could broaden the utility of 
PLL-g-PEG NP complexes. 
•  PLL-g-PEG NPs cause denaturation of albumin in their protein corona. 
Identifying means to reduce the binding and denaturation of corona 
proteins could reduce non-specific uptake of the PLL-g-PEG NPs. 
Additionally, identifying other proteins that bind to the NPs, both as part 
of the protein corona or as a result of albumin denaturation, would better 
characterize how these NPs interact with the biological environment.  
Determining how PLL-g-PEG NPs interact with a broader array of cell 
types would also aid in better understanding the behavior of these NPs in 
the physiological environment. 
• Further characterizing the immunogenicity of PLL-g-PEG NPs would also 
guide in the design of NPs that more effectively deliver proteins. While 
the uptake of CPP-functionalized PLL-g-PEG NPs by macrophages was 
described, characterizing the cytokine response of the macrophages to the 
NPs could also provide more insight into their immunogenicity. 
PLL-g-PEG NPs are capable of modifying proteins that change how they interact 
with cells and the biological environment. By better engineering how polymers and other 
materials interact with and deliver therapeutic proteins, novel protein delivery carriers 
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will be developed, which advance the efficiency of protein therapeutics and as well as 
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The grafting ratio of PEG onto PLL was determined using 1H NMR spectroscopy. 
The number of PEG chains grafted onto the PLL was calculated by integrating the peaks 
in the PLL-g-PEG NMR spectrum that correspond to protons of the PLL (-CH- at 4.15 
ppm) and PEG-amine linkage (-CH2CO-NH at 2.55 ppm) portions of the copolymer. 
First, the average number of α carbon protons corresponding to the number of lysines per 
mol of PLL was calculated by using the median molecular weight of the high, medium 
and low PLL polymers (50,000 kDa, 22,500 kDa, and 9,500 kDa) (Equation 1). Next, the 
relative number of mols of PEG linkages to mols of lysine residues was calculated by 
taking the quotient of the PEG linkage peak and PLL monomer peak areas (Equations 2). 
Once the relative number of mols of PEG linkages to PLL monomers was determined, 
the grafting ratio was calculated by taking the product of the number of lysines per PLL 
chain with the relative number of mols of PEG linkage per the relative number of mols of 
lysines (Equation 3).The calculation used to determine the grafting ratio and a sample 
1HNMR spectrum may be found below:
142 
 
S.1 Grafting Ratio Calculation and 1HNMR 
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Figure S.1 1HNMR Spectrum for PLL-g-PEG. The spectrum is for MMW 10 copolymer. The peaks at 4.15 ppm (PLL -CH-) and 







Candidate for the Degree of 
 
Doctor of Philosophy 
 
Dissertation:    SYNTHESIS AND FUNCTIONALIZATION OF POLY-L-LYSINE-
GRAFTED-POLYETHYLENE GLYCOL COPOLYMER 
NANOPARTICLE COMPLEXES FOR PROTEIN DELIVERY 
 
 






Completed the requirements for the Doctor of Philosophy in Chemical 
Engineering at Oklahoma State University, Stillwater, Oklahoma in July, 2018. 
 
Completed the requirements for the Master of Science in Chemical Engineering 
at Oklahoma State University, Stillwater, Oklahoma in July, 2014. 
  
Completed the requirements for the Bachelor of Science in Chemical 
Engineering at the University of Oklahoma, Norman, Oklahoma in May, 2011. 
 
Experience:   
 
Graduate Teaching and Research Assistant at the School of Chemical 
Engineering, Oklahoma State University, Stillwater, Oklahoma from January, 
2012 through May, 2018. 
 
Professional Memberships:   
 
Membership in AIChE  
 
 
 
 
